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Tetratricopeptide (TPR) repeats are a 34-residue helix-turn-helix motif that when repeated pack into a
superhelical structure. TPR domains are frequently found mediating protein-protein interactions, often
through a central groove. One protein complex bearing numerous TPR repeats is the Anaphase Promoting
Complex (APC). The anaphase-promoting complex (APC) is a multi-subunit complex, which orchestrates
mitotic cell cycles. APC is an E3 ligase in the ubiquitin cascade, and directs the 26S proteosome
degradation of cell-cycle regulators. Throughout mitotic progression, proteins that are key regulators of
the cell cycle are assembled with polyubiquitin chains by APC.
One domain of the human APC is comprised of four related TPR proteins, APC8, APC6, APC3, and APC7,
with each found in pairs. Crystal structures of some of these indicate that each has an N-terminal
dimerization domain and a C-terminal domain that APC3 extends away from the dimer interface. The TPR
C-terminal domains are thought to play major roles in mediating protein interactions within the APC.
The subunit APC3 plays major roles in regulating APC function. Within an APC3 dimer, each C-terminal
domain recruits the Ile-Arg motifs of substrate coreceptors Cdh1 (or Cdc20) and APC10. Cdh1 and APC10
together recruit substrates for ubiquitination. Therefore, it is important to understand the structure of
APC3, and how APC3 mediates interactions. To address this problem, I used a novel “hybrid TPR”
technology, in which some TPRs from a distant relative of APC3 are fused upstream of the C-terminal
domain from human APC3. This approach enabled determination of a 3Å resolution structure
encompassing the sequence of the APC3 C-terminal domain. Interestingly, only a fraction of the structure
resembles canonical TPR repeats. Interpretation of the crystal structure based on published structures of
complexes between TPR proteins and their partners, and on published electron microscopy structures of
APC-Cdh1-APC10, reveal that the region containing the Cdh1/APC10 binding site adopts 3 canonical TPR
repeats. The remainder of the portion of the structure corresponding to human APC3 is folded into an
alternative conformation, in which a helix from the atypical portion of APC3 buries the Cdh1/
APC10-interacting groove within the crystal. Accordingly, unlike wildtype APC3, the hybrid TPR APC3 fails
to bind Cdh1 and APC10. Nonetheless, the crystal structure of “hybrid TPR APC3 C-terminal domain”
allows the prediction of potentially important residues for binding to Cdh1 and APC10. Taken together, the
data reveal strengths and weaknesses of hybrid TPR technology for obtaining structural insights into TPR
subunits of multiprotein assemblies such as APC.

Document Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Program
Biomedical Sciences

Research Advisor
Brenda A. Schulman, Ph.D.

Keywords
Tetratricopeptide repeats, APC3, Hybrid TPR, E3 ligase, 26S proteosome

Subject Categories
Amino Acids, Peptides, and Proteins | Analytical, Diagnostic and Therapeutic Techniques and Equipment |
Chemicals and Drugs | Investigative Techniques | Medical Biochemistry | Medical Microbiology | Medical
Sciences | Medicine and Health Sciences

This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/400

Strengths and Weaknesses of Hybrid TPR Technology for Obtaining Structural and
Mechanistic Insights into TPR Proteins

A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Doctor of Philosophy
From The University of Tennessee

By
Shanshan Yu
December 2014

Copyright © 2014 by Shanshan Yu.
All rights reserved.

ii

DEDICATION
To my parents, Suozhen Chen, Muqing Yu
my brother, Ge Yu
and all my lovely friends of Memphis
for their love and support

iii

献 给

我的父母，陈锁珍， 余木清
我的弟弟，余戈
和孟菲斯我可爱的朋友们
谢谢你们的关爱与支持

iv

ACKNOWLEDGEMENTS

Above all, I would like to thank my mentor, Brenda Schulman, for immersing me
into the world of cutting-edge research and teaching me what it takes to keep doing a
leading science. The training will serve me well always. I want to thank Brenda for
creating a collaborative, informative and productive environment for doing sciences–
both in terms of recruiting fantastic people and providing great resources. Also, I would
like to thank committee members: John Cox, Eric Enemark, Roderick Hori and Stephen
White for their effort and the advices they put into guiding me through graduate school.
I would like to thank the members of the Schulman lab for all that they have
taught me and making this journey a fun one: Danny Scott for his insightful scientific
questions and suggestions; Dave Duda for all the brilliant crystallography tips and tricks;
David Miller for keeping the lab fully stocked and equipment always running; Hari
Kamadurai for all the experiment guides over the years; Jing Wang and Masaya
Yamaguchi for their help on projects we did together; Jeremy Frye for great advices
towards experiments and structural softwares; Ryan VanderLinden for all the scientific
discussion and suggestions; Nicholas Brown and Kuen-Phon Wu for the inspiring
conversation and help; Randy Watson a fellow PhD candidate, for all the scientific (and
nonscientific) discussion, advices sand being very helpful; Vladislav Sviderskiy for being
helpful and for all the fun times. Manjeet Mukherjee and Yumei Zheng (a fellow
graduate student), for sharing parts of the journey; Shelia Boezman for all the care,
administrative support and activity organization (not forgetting the chocolates, candies
and doughnuts); Jenny Olszewski, Shein Ei Cho and Omar Alsharif for being great lab
mates and the fun time together.
Additionally, my thanks are for: Billy Dye for the guidance with cloning and all
the smart jokes; Steve Kaiser for all the scientific discussions and the insights to the
career; Mathew “Matt-man” Calabrese for the taking the time to teach; Julie Monda, Alan
“DDR” Deng and Steven Seyedin for spreading the joy and for being ever helpful.
I would also like to thank the following people their tremendous help along the
way: Igor Polyakov for data collection and phase calculation. Darcie Miller for her help
with structure refinement; Luigi Iconaru, Hari Kamadurai, and Weixing Zhang for NMR
experiment operation and interpretations; John Bollinger and John Rogers for the
computer/IT support. David King for the Mass Spectrometry and Intact Mass data;
Amanda Nourse for the analytical ultracentrifugation data; Randy Watson, Vladislav
Sviderskiy and Jeremy Frye for the dissertation proofreading.
Finally, a big THANK YOU to my parents, my brother and all my friends who
have made this possible!

v

ABSTRACT
Tetratricopeptide (TPR) repeats are a 34-residue helix-turn-helix motif that when
repeated pack into a superhelical structure. TPR domains are frequently found mediating
protein-protein interactions, often through a central groove. One protein complex bearing
numerous TPR repeats is the Anaphase Promoting Complex (APC). The anaphasepromoting complex (APC) is a multi-subunit complex, which orchestrates mitotic cell
cycles. APC is an E3 ligase in the ubiquitin cascade, and directs the 26S proteosome
degradation of cell-cycle regulators. Throughout mitotic progression, proteins that are
key regulators of the cell cycle are assembled with polyubiquitin chains by APC.
One domain of the human APC is comprised of four related TPR proteins, APC8,
APC6, APC3, and APC7, with each found in pairs. Crystal structures of some of these
indicate that each has an N-terminal dimerization domain and a C-terminal domain that
APC3 extends away from the dimer interface. The TPR C-terminal domains are thought
to play major roles in mediating protein interactions within the APC.
The subunit APC3 plays major roles in regulating APC function. Within an
APC3 dimer, each C-terminal domain recruits the Ile-Arg motifs of substrate coreceptors
Cdh1 (or Cdc20) and APC10. Cdh1 and APC10 together recruit substrates for
ubiquitination. Therefore, it is important to understand the structure of APC3, and how
APC3 mediates interactions. To address this problem, I used a novel “hybrid TPR”
technology, in which some TPRs from a distant relative of APC3 are fused upstream of
the C-terminal domain from human APC3. This approach enabled determination of a 3Å
resolution structure encompassing the sequence of the APC3 C-terminal domain.
Interestingly, only a fraction of the structure resembles canonical TPR repeats.
Interpretation of the crystal structure based on published structures of complexes between
TPR proteins and their partners, and on published electron microscopy structures of
APC-Cdh1-APC10, reveal that the region containing the Cdh1/APC10 binding site
adopts 3 canonical TPR repeats. The remainder of the portion of the structure
corresponding to human APC3 is folded into an alternative conformation, in which a
helix from the atypical portion of APC3 buries the Cdh1/APC10-interacting groove
within the crystal. Accordingly, unlike wild-type APC3, the hybrid TPR APC3 fails to
bind Cdh1 and APC10. Nonetheless, the crystal structure of “hybrid TPR APC3 Cterminal domain” allows the prediction of potentially important residues for binding to
Cdh1 and APC10. Taken together, the data reveal strengths and weaknesses of hybrid
TPR technology for obtaining structural insights into TPR subunits of multiprotein
assemblies such as APC.
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CHAPTER 1. INTRODUCTION
APC Regulates Cell Cycle Progression
The anaphase-promoting complex (APC) is a multi-subunit Cullin-RING E3
ubiquitin ligase that regulates cell cycle progression through mitosis. One of the most
important functions of APC is to decorate key regulator proteins of the cell cycle with
polyubiquitinchains conjugated to initiate their proteolysis by the 26S proteasome.
Cell cycle brief introduction
The eukaryotic cell cycle is the process during which the cell replicates its
genomic DNA, and divides the DNA equally between two newly replicated daughter cell
through mitosis. The precise DNA duplication and cell division are critical to maintain
normal function during cell reproduction. The cell cycle is divided into a long interphase
and a relatively short mitotic phase. Interphase is the time that cells prepares themselves
for the process of cell division. It is further divided into phases of G1 (1st gap phase), S
(synthetic phase) and G2 (2nd gap phase). The cells grow in the G1 and G2 phases by
producing proteins and cytoplasmic organelles. In S phase, cells replicate DNA and
duplicate the genome. The duplicated genome is split during mitosis and separated into
two identical sets. The division of the entire cell (cytokinesis) followed mitosis, and
mitosis and cytokinesis together comprise the mitotic phase. Based on the order of
mitotic progression, mitosis is further divided into prophase, prometaphase, metaphase,
anaphase, and telophase prior to cytokinesis.
To ensure the appropriate complement of genetic material and equally distributed
cellular components between daughter cells, cells use “checkpoint” control mechanisms
to guarantee cell cycle events to occur in a precise order.
An overview of ubiquitin cascade
The ubiquitin cascade is an event prior to the major pathway for misfolded or
unwanted protein degradation. Ubiquitin is a small protein (~8.6kDa) and it is normally
covalently attached to proteins through its C-terminal glycine residues linked to the lysine
residues of proteins via an isopeptide bond. This process is known as ubiquitination.
Following the first ubiquitin, a second ubiquitin molecule is added to the first one by
linking its last C-terminal glycine residue to a lysine of the first ubiquitin. The repeating
of this step eventually yields a polyubiquitin chain. Ubiquitin has seven lysine residues
that may serve as ubiquitination points, the K48-linked and K63-linked polyubiquitin
chains being best characterized. The K48-linked polyubiquitin chain mediates
proteasome-dependent degradation while the K63-linked chains are associated with
cellular signaling (1-3).
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Three types of enzymes, E1s, E2s and E3s, mediate the ubiquitination cascade.
They are also known as ubiquitin-activating enzymes, ubiquitin-conjugating enzymes,
and ubiquitin ligases, respectively. At the start of the ubiquitination cascade, ATP
activates ubiquitin by forming a C-terminal acyl adenylated ubiquitin. The cascade
continues with an E1 catalytic cysteine forming a thioester bond with ubiquitin Cterminal carboxyl group. Catalyzed by E2, the ubiquitin transfers from E1 to an active E2
cysteine through a trans-esterification reaction. At the final step, E3 specifically
recognizes substrates and catalyzes ubiquitin transfer to Nε-amino group of substrate or
ubiquitin lysines.
In the ubiquitination cascade pathway, E1 can bind with many E2s, which can
bind with hundreds of E3s in a hierarchical way. Correspondingly, there are two E1s, tens
of E2s and hundreds of E3s in the human proteome to mediate the ubiquitination
targeting thousands of substrates. E3 ligases are generally divided into two categories:
HECT (Homologous to E6-AP Carboxyl Terminus) E3s and RING (Really Interesting
New Gene) E3s. HECT E3s form a covalent E3-ubiquitin intermediate (via a thioester
bond with the ubiquitin C-terminus) to mediate ubiquitin transfer (4), whereas RING E3s
directly transfer ubiquitin from E2 enzymes to substrate without a covalent intermediate.
The RING domain does not directly participate in the reaction (5). RING E3s represent
the largest structural class of ligases and APC (Anaphase-Promoting Complex) belongs
to the RING E3 ligase family (Figure 1-1).
The APC directs cell division via substrate destruction
The APC orchestrates mitosis and G1 by sequentially promoting degradation of
key cell-cycle regulators. APC is found in its active form at the onset of mitosis (Figure
1-2). Some well-studied APC substrates, notably mitotic Cyclins, Securin, Geminin,
AuroraA and Hsl1, could be divided as early substrates and late substrates based on their
degradation timing. (i) Cyclin A and Nek2A are early substrates and are recognized by
APC at prometaphase (6, 7). Cyclin A forms complexes with Cdk1 and Cdk2 that support
S-phase and G2-phase progression. Nek2A is a mammalian kinase required to ensure the
correct formation of mitotic spindles at mitosis onset. Decreasing the cellular
concentrations of Cyclin A and Nek2A allows mitosis to enter into metaphase. (ii) To
promote cell cycle transition from metaphase to anaphase (when sister chromatids
separate), APC assembles polyubiquitin chains to degrade Securin. The degradation of
Securin releases Separase, a protease, which advances sister chromatid separation by
cleaving Cohesin (8, 9). (iii) Another substrate that is degraded rapidly during metaphaseanaphase transition is Geminin. Geminin inhibits DNA replication during S, G2, and M
phases by preventing the incorporation of the MCM complex (mini-chromosome
maintenance complex). Destruction of Geminin permits replication in the succeeding cell
cycle (10). (iv) During late mitosis, APC also targets Cyclin B (and other mitotic Cyclins)
for degradation, which then deactivates Cdk1. The decreased activity of Cdk1 plays a
critical role in mitotic spindle disassembly and chromosome decondensation, which in
turn promotes cell exiting from mitosis and entry into cytokinesis (11); (v) Aurora A is
another late substrate which is quickly degraded after mitosis. Aurora A is essential for
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Figure 1-1.

APC functions as an E3 ligase in ubiquitination cascade.

A ubiquitin (yellow) is initially activated by an E1 (activating enzyme, cyan) and is
driven by hydrolysis of an ATP molecule. The ubiquitin then forms a thioester linkage
with the catalytic cysteine of the E1. Next, the E1 recruits an E2 (magenta) and transfers
the ubiquitin to the E2 catalytic cysteine. Finally, with the aid of the E3, APC (light
orange), the ubiquitin is transferred to a lysine on the target substrate.
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Figure 1-2.

The order of APC substrate destruction.

The activity of APC is first inhibited by a protein complex called the spindle assembly
checkpoint (SAC), which interacts with Cdc20 and thereby blocks substrate recruitment
by APC. Cyclin A and the kinase Nek2A are two of prometaphase targets and they are
ubiquitinated by APC without being recognized by Cdc20. SAC is inactivated when all
the sister-chromatid pairs are attached to the spindle, allowing an activated active APC to
target metaphase substrates, like Securin and Cyclin B. Cyclin destruction leads to cyclindependent kinase (Cdk) inactivation, which results in the dephosphorylation and
activation of the second APC activator, Cdh1. APCCdh1 triggers the destruction of various
targets at late mitosis (from anaphase to telophase), like Geminin, Cdc20 and Aurora A.
These substrates are degraded at different times, presumably providing mechanisms that
order late mitotic events. Key mitotic events are labeled out in text boxes along with the
cell-cycle time course.
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proper centrosome separation once the mitotic spindle is formed (12). (vi) Hsl1 is a
substrate of the budding yeast APC (13), which accumulates after G1 phase as cells begin
to bud but disappears in late mitosis. Hsl1 promotes the degradation of yeast cytoskeletal
proteins and allows cells to proceed to mitosis (13).
The APC adopts a similar two-step mechanism to other ubiquitin ligases to
assemble a polyubiquitin chain. The E2 UbcH10 functions as a “priming” E2, whereby
the APC specifically mono-ubiquitinates substrates (14). The second E2 Ube2S elongates
the ubiquitin chain. The APC triggers substrate degradation by assembling K11-linked
ubiquitin chains, and the specificity of this chain formation depends on a surface of
ubiquitin (15). APC is the largest of the RING E3 family, which are characterized by
direct ubiquitin transfer from E2 to substrates without forming a covalent intermediate
(16, 17). APC positions both a substrate and a ubiquitin conjugated UbcH10 in close
proximity to facilitate ubiquitin transfer to substrate lysines.
APC Architecture and Subunit Organization
APC subunit organization
The human APC consists of 14 subunits and has a molecular weight around
1.2MDa (Table 1-1). Based on biochemical and genetic data, the complex is considered
to have two large domains, called the “arc lamp” and the “platform”, which together
enclose a central cavity (Figure 1-3). The arc lamp is comprised of tetratricopeptide
repeat (TPR) proteins APC7, APC3, APC6, and APC8 with small subunits APC16,
Cdc26 and APC13. The arc lamp is therefore also called TPR arm. The platform consists
of APC1, APC4, APC5, and APC15 (18). The catalytic core of APC is composed of
subunits APC2 and APC11, which are analogous to the Cullin and Rbx1 subunits of
Cullin-RING ligases in the SCF superfamily (19). The Cullin domain of APC2 interacts
with the RING-finger APC11, which potentially mediates interactions with the ubiquitin
conjugated E2s (UbcH10 and Ube2S). APC2 and APC11 are neighbored by APC1 inside
the complex, whereas TPR subunits co-localize to a more distal region to APC1.
With respect to human APC, APC7 is the most peripheral TPR subunit of the “arc
lamp”, and APC8 is the most internal subunit. APC6 stacks between APC3 and APC8,
and APC3 stacks between APC7 and APC6. Yeast APC lacks the APC7 subunit, and
therefore yeast APC3 (Cdc27) is the most peripheral TPR protein. Each TPR subunit
forms a homo-dimer through their N-terminal domains, and four homo-dimers spirally
stack together and constitute a TPR arm (20). The TPR arm has the flexibility to support
APC switching overall conformation between open and closed status (21).
The small subunit APC16 was recently discovered and characterized (22) to be
important for maintaining APC activity towards mitotic substrates. APC16 associates
with both APC3 and APC7, and it may function to stabilize interactions between them.
Another small subunit, APC13, interacts with APC8 and is reported to have a function of
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Table 1-1.

The APC core and regulatory subunits.

H.
sapiens

S.
cerevesiae

S.
pombe

Molecular Stoichiometry
Structure motif
mass
(kDa)
216.5
1
PC repeats
93.8
1
Cullin homology
92.6
2
TPR

APC1
APC2
APC3

APC1
APC2
Cdc27

Cut4
APC2
Nuc2

APC4

APC4

Lid1

92.04

1

APC5
APC6
APC7
APC8
APC10

APC5
Cdc16
—
Cdc23
Doc1

APC5
Cut9
—
Cut23
APC10

85.1
71.7
63.2
68.3
21.2

1
2
2
2
1

APC11
APC13
APC15
APC16

APC11
Swm1
—
—

APC11
APC13
APC15
—

9.84
8.5
14.28
11.67

1
1
1
1

Cdc26

Cdc26

Hcn1

9.78

2

Cdh1

Cdh1

55.18

1

Cdc20

Cdc20

54.72

1

β-propeller, extended
TPR
Extended TPR
TPR
TPR
TPR
β-barrel, IR tail
peptide
RING-H2 finger
A few α-helix
A few α-helix
C-terminal long αhelix
Unstructured Nterminal domain, Cterminal α-helix
C-box, WD40 repeat,
IR tail peptide
C-box, WD40 repeat,
IR tail peptide

Molecular mass corresponds to H. sapiens subunits.
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Function

Scaffolding subunit
Catalytic subunit
Scaffolding subunit, recruit
substrate co-receptors
Scaffolding subunit
Scaffolding subunit
Scaffolding subunit
Scaffolding subunit
Scaffolding subunit
Substrate co-receptor
Catalytic subunit
Stabilize APC8
Unknown
Stabilize APC7 and APC3
Stabilize APC6

Activator, substrate coreceptor
Activator, substrate coreceptor

Figure 1-3.

The schematic of the APC subunit topology and the APC architecture.

(a) Schematic representation of human APC showing approximate subunit topology
based on biochemical and genetic data cited in the text.
(b) 3D model of human APC. The ‘arc lamp’ and the ‘platform’ domains enclose a
catalytic cavity. Each subunit is assigned to its corresponding density. The EM map,
APCCdh1-Emi1 is reprinted from the open source EM databank (EMD 2354) (23, 24).
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stabilizing association of APC3 and APC6 (25). Cdc26 was proven to be essential for
proper folding of APC6 (26, 27). APC6 could not be expressed in vitro without Cdc26. In
the budding yeast, the deletion of Cdc26 resulted in reduced levels of APC6 and APC3
incorporation into the APC (28).
The largest subunit in the platform of APC is APC1, which has a molecular
weight more than 200kDa. APC1 C-terminal domain has nine pentatricopeptide repeats
(PPR), which fold into the helix-turn-helix structure similar to TPR motifs. APC4
associates with APC5 (29) and subunits APC1, APC4, APC5 interdependently associate
with each other to form the platform. APC8 connects the TPR arm with the platform.
APC recruits co-activators through TPR subunits
Without the co-activators Cdh1 and Cdc20, APC is an inactive E3 ubiquitin
ligase. Cdh1 and Cdc20 are not the constitutive subunits of APC and they are recruited to
the complex alternatively during cell cycle phases. By switching between Cdh1 and
Cdc20, APC specifically targets various cell-cycle regulators during cycle procession.
TPR subunits APC3 and APC8 contribute to the recruitment of Cdh1 and Cdc20.
TPR structure motif is a protein-protein interaction module that consists of two
antiparallel α-helices. Most TPR proteins are characterized by continuous α-helices as
their secondary structures (30). Both APC3 and APC8 are predicted to have 14 TPR
motifs and the N-terminal 6 TPR motifs mediates homo-dimerization.
APC3 is required for the Cdc20 and Cdh1 association with APC. Both yeast and
human APC EM structures reveal that Cdh1 localizes adjacently to the C-terminal
domain of a molecule within the APC3 homo-dimer (31, 32). Cdh1 could be specifically
cross-linked to APC3 through multiple crosslinking compounds (33). In the APC3deleted yeast APC, Cdh1 and Cdc20 binding to the complex are dramatically decreased
compared to the wild type APC (18, 33). These APCs lost the ability to assemble long
ubiquitin chains onto substrates (the ubiquitin number of most chains is less than three),
which contributes to the mutated complex having a 100-fold lower activity than wild type
APC (33, 34).
APC3 C-terminal TPR domains were predicted to recruit co-activators, Cdh1 and
Cdc20 through their C-terminal Ile-Arg (IR) tail motif (35). The double mutation of two
conserved residues (N548A and L579A) in yeast APC3 raised the Cdh1 dissociation rate
from APC without affecting other subunit incorporation. The APC3 mutant
(N548A/L579A) reduces the APC ubiquitination activity more than 5-fold once it is
incorporated into APC (34). The conserved residues N548 and L579 sit on the α-helices
of TPR8 and 9 of yeast APC3, and therefore TPR8 and 9 are believed to form a binding
groove responsible for co-activator recruitment.
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Co-activators interact with the APC through multiple interactions
Cdh1 and Cdc20 are recruited to APC3 through its C-terminal Ile-Arg (IR) tail
motif. The last two Isoleucine and Arginine residues of Cdh1, Cdc20 and APC10 are
highly conserved across species (Figure 1-4). APC10 is also found to associate with
APC3 through its C-terminal IR motif (34, 36). Multiple research groups have found that
the IR-tail deleted/mutated Cdh1 or Cdc20 have APC-binding defects and contribute to
APC-activation defects (18, 34, 37). The Arginine to Lysine mutation of the IR-tail
disrupted the interaction between Cdh1 and APC (38). IR-tail peptides of Cdc20 and
Cdh1 could bind to APC3 and the peptides inhibit in vitro APC ubiquitination by
competing with co-activators recruitment to APC (37). The IR-tail peptide of Cdh1 is
essential for budding yeast viability whereas C-terminal IR-tail peptide of Cdc20 is not
(18, 33). This may reflect differences in affinities of multiple Cdh1 and Cdc20 binding
sites on APC, although future studies will be required to know how much each binding
site contributes.
Cdh1 and Cdc20 also have an eight-residue C-box motif near the N-terminus. The
C-box enhances the ubiquitination activity of APC though the mechanism is not well
understood. The C-box containing Cdc20 fragment (N-terminal fragment) enabled the
ubiquitination of Nek2A to be mediated by the substrate interaction domain, WD40
domain (a domain comprised of tandem copies of WD40 repeat) (39). The C-box deleted
Cdh1 caused a large reduction of APC ubiquitination activity. The co-activator C-box
might promote a change in APC conformation that is independent of the activators’ other
domains.
A xenopus Cdc20 C-box containing protein fragment was discovered to interact
with APC through subunit APC3, and the affinity is weaker than the IR motif-APC3
interaction (40). Multiple residues of Cdh1 C-box, WD40 domain and IR-tail could be
cross-linked to APC3, and the residues of the IR-tail demonstrated much stronger crosslinking interaction than others. However, all the cross-linked interactions disappeared
once the C-terminal IR peptide is deleted (33). The IR-tail deletion increases Cdh1 partial
dissociation from APC, and double deletion of C-box and IR motif further increases
Cdh1 dissociation (34, 37). Cdh1 and Cdc20 seem to have multiple sites mediating lowaffinity interaction with APC and their IR motifs are responsible for anchoring the coactivators into the correct binding groove of APC3.
The mutation of yeast APC8 conserved residue (N405A) also affected Cdh1
recruitment. APC3 (N548A and L579A), APC8 (N405A) double-mutant APC caused cell
cycle arrest in metaphase with high levels of Cyclins (34). This APC8 mutant also
demonstrates a higher Cdh1 dissociation rate. The mutation of Cdh1 C-box greatly
reduced the activity of APC8 mutant incorporated APC. Therefore, the residue Asn405
(N405) in APC8 is likely to interact with a third, unknown site on Cdh1.
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Figure 1-4.

Sequence alignment of C-terminal APC10, Cdh1 and Cdc20.

Sequence alignment of the C-terminal Cdh1, Cdc20 and APC10 from human (Hs),
Mouse (Mm), Drosophila melanogaster (Dm), Arabidopsis thaliana (At), Dictyostelium
discoideum (Dd), Saccharomyces cerevisiae (Sc), Schizosaccharomyces pombe (Sp). The
last two residues, Isoleucine and Arginine, are highly conserved across different species.
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Substrate recruitment to APC through the co-activators and APC10
APC has weak interaction with substrates without its co-activators (38, 41). The
role of the co-activators is to act as a substrate recognition subunit and recruit substrates,
which is analogous to the F-box protein receptors of the SCF. Substrates of the APC
contain conserved APC-targeting sequence elements: the KEN and destruction box (Dbox). D-box and KEN box motifs are characterized with peptide sequences
RxxLxxI/VxN and KENxxxN/D, respectively.
Cdh1 and Cdc20 each contain a WD40 domain which folds into a seven-blade βpropeller structure. This domain functions as a destruction box (D-box) receptor to bind
substrates. The fact that WD40 domains of Cdc20 and Cdh1 could be cross-linked to
substrates in a D-box-dependent manner confirms a role for co-activators in recruiting of
substrates to the APC core (33, 42). Moreover, residue mutations of the evolutionarily
conserved surface of WD40 domains abolish crosslinking interactions with substrates
(33).
Human and yeast APC EM structures explicitly revealed the interaction between
Cdh1 and substrates. The apo APC EM map demonstrated that Cdh1 and APC10 have
separated density in close proximity. APC10 is an APC subunit localizing at the opposite
side of the catalytic center from Cdh1. When the substrate Hsl1 is bound, the β-propeller
domain (WD40 domain) of Cdh1 shifted approximately 7Å towards APC10. The
repositioning of Cdh1 created a well-defined density to bridge the gap between them
(Figure 1-5). The KEN box of Hsl1 alone also promoted repositioning of Cdh1 towards
APC10, but there wasn’t connecting density between KEN box and APC10. It seemed
that only the D-box of substrates contributed to the physical connection between Cdh1
and APC10. Cdh1, Hsl1 and APC10 together form a three-layer structure (31, 32).
Arginine and Leucine residues appear as two invariant residues inside the D-box
motif (RxxLxxI/VxN), and the C-terminal Asparagine residue is less conserved.
Mutations of Arginine and/or Leucine eliminate the recruitment of this motif to the coreceptors. The D-box of the substrates directly interacts with the WD40 propeller
structure of Cdh1, and this interaction is essential for ubiquitination processivity (33).
The mutated D-box and KEN box also abolished substrate recognition and recruitment to
the APC (34, 38, 41).
The use of two distinct motifs for substrate recognition introduces a greater
degree of substrate specificity. APCCdh1 is also able to ubiquitinate substrates containing
only a KEN box motif, such as Cdc20 and Sororin. Contrastingly, APCCdc20 recognition
of substrates requires the D-box motif. The conformation of the KEN and D-box are
different when they are bound to Cdc20. It has recently been reported that the KEN box
folds into an underwound helix, whereas the D-box is potentially an extended structure
(Figure 1-5) (43, 44). The optimal spatial arrangement of KEN and D-box is not well
understood. But the Cdh1 inhibitor Acm1 and Mes1 have the spacing of 18 and 24
residues, respectively, between the KEN and D-box motifs, which optimize their affinity
to the co-activators (45).
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Figure 1-5. Detail and schematic demonstration of Cdh1 and APC10 as APC
substrate co-receptors.
Left: Schematic diagram of the substrate-recognition module responsible for the D-box
and KEN box binding, and Cdh1 and APC10 recruitment to the APC3 homo-dimer. Dbox is represented as a box in the interface between Cdh1 and APC10. Right: Details of
the Cdh1 and APC10 functioning as co-receptors to the D-box. Hsl1’s D-box is recruited
to Cdh1 between blade 1 and 7, while KEN box is recruited to the surface at the center of
the bottom side of the WD40 domain. APC10 faces toward D-box with its substratebinding pocket. APCCdh1-Emi1 EM map (EMD 2354) (23) is used for the structural
demonstration.
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It is also not well understood whether there is an optimal distance between a
target Lysine (the ubiquitin acceptor residue) and the KEN or D-box motifs. Randall
King’s group reported that 15 residues between the D-box and the target Lysine is
sufficient to support the degradation of the D-box fused proteinA (46). A C-terminal
Lysine immediately following the D-box peptides (of CyclinB1 and Securin) functioned
as a ubiquitin acceptor (33). Lysines preceeding the D-box in Cyclin B from S. pombe
also accepted ubiquitins and mutating them made a D-box containing peptide nonubiquitinable (47).
The contribution of APC10 to APC processivity
APC10 is a constituent subunit of the APC and binds to APC3 through its Cterminal IR motif. APC10 acts as another co-receptor for the APC substrates (31, 32, 48,
49). APC10 adopts a β-barrel (jellyroll) fold with a binding pocket structure, both
structurally similar to galactose oxidase (36, 50). APC10 is necessary for optimal
Cdh1/Cdc20-dependent substrate recognition, through which APC10 contributes to
substrate processivity (38). The mutation of conserved residues in the APC10 binding
pocket affected substrate processivity, and the deletion of the entire subunit impaired
polyubiquitin assembly in a D-box-dependent manner (48, 49). The docking of the
APC10 crystallographic model into APC EM maps displays that a conserved loop of
APC10 faces toward the substrate D-box (Figure 1-5). However, the interaction affinity
between APC10 and substrates is pretty low. Da Fonseca and Kong et al demonstrated
the weak interaction of APC10 to the substrate D-box through HSQC-type NMR
experiments, whereas the substrate KEN box didn’t appear to interact (32).
There is a bipartite model to interpret the contribution to the substrate recruitment
by APC10. In this model, the D-box of substrates may form a divalent connection to
bridge a co-activator and APC10. APC10 potentially stabilizes the association of coactivator-substrate to APC through this bipartite interaction (divalent bridge), which
probably results in a higher ubiquitination processivity. The mutant APC lacking the
APC10 subunit displays a 50-fold reduction in the Cyclin recruitment and the Cyclin B
peptides interacted more efficiently with Cdc20 when it is bound to the holoAPC (33,
49). Hsl1 enhanced the Cdh1 association to the APC in vivo and Cyclin B enhanced this
association in vitro (34). Individually, both the co-activators and APC have low affinity
and specificity for substrates (41). APC10 probably stabilizes Cdh1 binding to APC
through the D-box of substrates.
APC10 promotes APC processivity in an E2 independent manner. APCΔAPC10
produces less ubiquitinated Cyclins due to the poorly bounded substrates to the complex
(49). But the interactions between the APC and E2s are not compromised in the absence
of APC10, and E2s show similar effects to promote the activity of both wild type APC
and the APCΔAPC10.
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TAME is an IR-tail mimic APC inhibitor
TAME (tosyl-L-arginine methyl ester), is a small molecule, which structurally
resembles the IR motifs of the APC co-activators and APC10. The benzyl ring of the
tosyl group mimics the hydrophobic interaction contributed from Isoleucine of the IR
motifs. TAME is reported to inhibit the APC activation by preventing Cdc20 and Cdh1
binding. In an assay TAME almost completely disrupted Cdc20 association to the APC
and prevented polyubiquitin chains from being assembled onto Cyclin B (51). TAME
specifically antagonizes the IR motif-dependent interactions without inhibiting other
interactions between the co-activators and APC. The compound disrupted the IR-tail
peptides which were cross-linked to APC but didn’t affect the recruitment of the IR motif
deleted co-activators or the C-box only fragments of the co-activators (40). Similar to the
IR-tail peptides reduction of the APC Kcat, TAME slows the Kcat of the APCCdc20 by a
~55%, while the amount of the Cdc20 associated to the APC is not reduced (51).
Whether or not TAME affects APC10 is not well understood.
TAME induces Cdc20 dissociation from the APC by promoting Cdc20
ubiquitination. The ubiquitination of Cdc20 is upstream of the C-box, reducing its
binding affinity for the APC. Cyclin B promotes the Cdc20 binding to the APC and
suppressed Cdc20 ubiquitination (40, 51). A cell-permeable prodrug (proTAME) is
capable of inhibiting APC-Cdh1 activation during S phase, and induces mitotic arrest in a
SAC dependent manner. HeLa cells treated with 12 μM proTAME were arrested in
metaphase without mitotic spindle disruption. ProTAME also greatly increased mitotic
duration in asynchronous hTERT-RPE1 cells (51).
Crystallography study of APC subunits
It is still mysterious why the APC is such a large complex, comprised of a large
number of subunits. Structural studies of the APC subunits have yielded crystallographic
structures of numerous TPR subunits and substrate co-receptors: APC6-Cdc26 complex
from human and yeast (PDB code: 3HYM, 2XPI), APC3 N-terminal dimer domain from
E. cuniculi (PDB code: 3KAE), and APC8 N-terminal domain from S. pombe. The coreceptor APC10 structures were determined from both the yeast and human proteins, but
the C-terminal peptides and IR motifs are missing in these atomic models (Figure 1-6).
The WD40 domain of yeast Cdh1 was co-determined with Cdh1 inhibitor Acm1 (PDB
code: 4BH6). Cdc20 of both human and yeast were determined together with the MCC
complex subunits (PDB code: 4AEZ, 4GGD).
From these studies, APC3, APC6 and APC8 were found to form homo-dimers,
with an interlocking dimer interface mediated by the self-association of their N-terminal
TPR motifs. The overall structure of APC6 displays a TPR superhelix created by seven
successive TPR motifs. The superhelix features each APC6 subunit/monomer in a rodlike structure of a continuous 14 TPR motifs (27). The N-terminal 13 residues of Cdc26
extend into the inner concave groove of the APC6 superhelix (from the C-terminal
APC6) and stabilize the superhelix conformation through intimate interactions
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Figure 1-6.

Crystal structures of APC10, Cdh1, and Cdc20.

Cartoon views of the overall structures of all the available atomic models from APC10,
Cdh1 and Cdc20. All the atomic models have C-terminal around 20 residues absent.
Human and yeast APC10 both adopt β-barrel structure except yeast APC10 has a longer
N-terminal α-helix. The models of Cdh1 and Cdc20 miss the N-terminal ~160 residues,
but Mad2 interaction domain of yeast Cdc20 is visible in structure.
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(Figure 1-7). The rest of Cdc26 forms an α-helix that packs against the APC6 C-terminal
TPR α-helix (26, 27).
The C-terminal 9 TPR motifs of E. cuniculi APC3 are absent from its crystallized
N-terminal dimer. The C-terminal APC3 was predicted to form a continuous TPR
superhelix like APC6. Among all of the C-terminal TPRs, TPR8 and TPR9 are predicted
to be the motifs recruiting the co-activators and APC10 through their C-terminal IR
peptides. Matyskiela et al predicted the conserved Asparagine of TPR8 and Leucine of
TPR9 both engaged in the interactions with the Cdh1 IR motif (34).
The structure of Cdh1-Acm1 demonstrates the D-box of the substrates and
inhibitors binding to an APC co-activator. The D-box of Acm1 binds to an inter-blade
groove on Cdh1 (between blade 1 and 7) and the KEN box binds to a conserved surface
at the center of the topside of WD40 domain. The KEN box recognition sites on Cdh1 are
likely to be universal through all species. Acm1 uses a motif A and an α-helix, to
specifically target Cdh1 but not Cdc20. The A motif aligned parallel with β–sheet blade 3
and interacts with another inter-blade channel (between blade 3 and 4), which is less well
conserved than the D-box and KEN box interaction regions. Acm1-Cdh1 forms a
heterodimer to inhibit the APC activation.
The structure of Cdc20 is determined within the MCC complex (mitotic
checkpoint complex, PDB code: 4AEZ, 4GGD). Human Cdc20 is comprised of a WD40
domain forming a β propeller with a preformed KEN box binding site at its top surface.
Both human and yeast Cdc20 use a deep hydrophobic pocket at the surface of blades 1
and 7, to interact with the D-box Leucine residue (RxxLxxI/VxN) (43, 44). The pocket is
created from the conserved non-polar residues on the surface. The mutants of D-box
interacting residues diminish the ubiquitination ability whereas the mutants of KEN boxbinding site lack such deficiency. Blocking the Leucine-binding pocket with small
molecules may be a potential mechanism to inhibit APCco-activator activity (43, 44).
The affinity of Cdc20 for the substrate D-boxes is weaker than Cdh1. Unlike
Cdh1, Cdc20 residues could not crosslink to substrates the way Cdh1 could, although
they localize at the equivalent sites of the WD40 domain (33, 43). KEN box contacting
sites are also dispensable for APCCdc20 ubiquitination of Securin, where the same sites on
Cdh1 are essential for APCCdh1 activity (43).
An alternative structural approach to study APC assembly is through Electron
Microscopy. Yeast APC EM structures were determined using cryo-electron microscopy,
whereas the human and Xenopus structures were determined by the approaches of both
cryo- and cryo-negative stain electron microscopy. The effective resolution is of the order
of 10-20Å.
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Figure 1-7.

APC6 adopts a superhelix structure.

Surface density of S. pombe and human APC6 structure (left) demonstrate that APC6
continuous TPR motifs form the superhelix tertiary structures. Two structures were
superimposed onto each other with an r.m.s.d of 1.77Å (right), and N-terminal Cdc26
stabilizes APC6 tertiary structure through interactions with the superhelix inner groove.
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APC Activity Regulation
There are multiple complexes involved in cell-cycle control system to coordinate
cell cycle progression. The Emi1 (early mitotic inhibitor 1) protein and mitotic
checkpoint complex (MCC) inhibit the APC activity by mimicking substrate recognition
motifs; the D-box and/or KEN box.
Emi1 inhibition
Emi1 is an inhibitor of the APC and it was first discovered due to its role in
preventing premature APC activation in early mitosis (52). The APC inhibition by Emi1
is accomplished through a combination of structure motifs: a D-box, a conserved zincbinding region (ZBR), a linker linking D-box to ZBR and a highly conserved C-terminal
LRRL tail (Leu-Arg-Arg-Leu) (53). The D-box of Emi1 allows the protein to mimic the
substrates interaction with the APC and Emi1 is recruited between Cdh1 and APC10
(23). Comparing with an isolated D-box peptide from the yeast APC substrate Hsl1, the
isolated Emi1 D-box is relatively weak, although Emi1 competes with the D-boxdependent substrates to be recruited to the APC (23, 54).
The ZBR of Emi1 provides an APC E3 ligase antagonizing activity (52, 54).
Interestingly, the mutation of the Emi1 ZBR converts Emi1 to a D-box-dependent APC
substrate (54). The linker between the D-box and ZBR contributes to inhibition with its
specific side chains. The Emi1 C-terminal tail is a specific inhibitor to the Ube2Sdependent ubiquitin-chain formation, and ZBR and C-terminal tail synergize to block
chain elongation. Much of the Emi1 is predicted to be intrinsically disordered, and this
disorder has implications for an ability to span over a broad distance of the APC catalytic
center, although this inhibitor has a relatively small size. The Emi1 D-box, linker, ZBR
and tail synergistically block both the substrate binding to the APC and ubiquitin chain
elongation by the APC and Ube2S (23).
MCC inhibition
The MCC (Mitotic Checkpoint Complex) is a multi-subunit protein complex that
is activated by the spindle assembly checkpoint (SAC). The MCC includes the coactivator Cdc20, which assembles with the other MCC proteins and loses its APC
activation function.The blocked Cdc20 leads to an inhibited degradation of Securin and
Cyclin B (substrates of APCCdc20) until late mitosis. This regulatory network of the APC
activity is contributed from three complexes to ensure that chromatids are attached to
mitotic spindles and well aligned before onset of the anaphase. However, Nek2A and
Cyclin A still escape MCC-mediated inhibition (55), being targeted instead at
prometaphase for ubiquitin-mediated proteolysis.
A couple of EM studies have demonstrated that the MCC localizes to the front
end of the platform domain (21), and Cdc20 is partially overlapped with MCC. MCC sits
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in the lower region of the APC cavity. Mad2 contacts the TPR subunits APC8 and APC5,
whereas Mad3 interacts with APC1 (44). Checkpoint inhibition of APCCdc20 requires the
binding of a Mad3 (also called BubR1) KEN box to Cdc20. Due to this mechanism, Cdh1
is required for the exit of mitosis.
The MCC can be assembled in vitro from recombinant Mad2, Mad3 (BubR1), and
Cdc20 proteins in the absence of kinetochores. Mad2 and Mad3 (BubR1) bind directly to
Cdc20 and together they inhibit the APCCdc20 activity towards ubiquitinating Securin and
Cyclin B. The conserved N-terminus of BubR1 that is essential for MCC assembly
incorporates a KEN box, and the BubR1 N-terminus adopts a helix–loop–helix (HLH)
structural motif. The HLH motif simultaneously binds Mad2 and Cdc20, orienting the
KEN box towards its binding residues on the receptor Cdc20 (44). Binding of the Nterminal Mad3 to Cdc20 is KEN box-dependent (43), and the same KEN box also
promotes Mad3-dependent APC-mediated Cdc20 degradation (56), which suggests that
Mad3 plays a role in positioning Cdc20 for ubiquitination mediated by the APC catalytic
subunits (44). The EM structures of the APC-MCC complex demonstrate that the D-box
receptor residues are directed towards, but not in contact with, the substrate co-receptor
APC10 (21, 44). Comparing with the Cdh1 position on APCCdh1, Cdc20 is displaced
downwards towards APC5, and it is lower than Cdh1. This lower position may facilitate
Cdc20 ubiquitination. Furthermore, the lower position of Cdc20 prevents its D-boxbinding site from generating a bipartite D-box co-receptor with APC10 (44).
Substrate specificity controlled through co-activators
The APC-mediated coordination of cell-cycle progression is achieved through the
temporal regulation of APC activity. Cdc20 activates the APC during early mitosis when
Cdh1 is inhibited by its N-terminal phosphorylation. The N-terminus of Cdc20 alone,
without the substrate-binding WD40 domain, is able to activate the APC catalytic
activity. The APCCdc20 reduces mitotic Cdk activity through the degradation of Cyclins
which are required for Cdk activity, which in turn stimulates the APCCdh1 activity. This
then leads to the APCCdh1 ubiquitinating Cdc20 and deactivating the APCCdc20. The
APCCdc20 and APCCdh1 have different substrate specificities. Dynamic changes in the coactivator positions relative to core APC subunits may provide the combinations of
substrate-recognition interfaces.
In addition to the D-box and KEN box binding sites, the APCco-activators utilize
additional recognition sites to bind substrates and regulatory proteins. The C-terminal
Met-Arg (MR) residues of Nek2A are structurally related to the IR-tails of the coactivators and APC10, and are directly recruited to APC in a MR-dependent manner (55).
The Nek2A MR tail may engage the IR motif binding sites of APC3. Cyclin A is
recruited to the APC through its binding partner Cks1(56) that recognizes the
phosphorylated APC3 of the TPR arm (57).
The N-terminal Cdc20 facilitates Nek2A destruction in a C-box-dependent
manner in Cdc20-depleted cells (39). Cdc20 is required for the degradation of Nek2A and
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Cyclin A, but it does not mediate their binding to the APC at prometaphase. This renders
their degradation insensitive to the mitotic checkpoint complex (39, 55, 57). The
ubiquitination of Cdc20 is not required to release it from the checkpoint complex, but to
degrade it to maintain mitotic arrest (56).
APC activity regulation via UbcH10 auto-ubiquitination
Coupling of APC activity to E2s provides another mechanism of regulation. Once
a substrate is bound to APC, several different ubiquitin-conjugating enzymes will
catalyze the ubiquitin chain assembly. UbcH10 or UbcH5 (Ubc4 in yeast) catalyzes
mono-ubiquitination onto the substrate lysines, followed by Ube2S (Ubc1 in yeast)
assembling a Lys11-linked poly ubiquitin chain onto the pre-attached ubiquitins (58-60).
The Ubc1 of S. cerevisiae assembles a Lys48-linked poly ubiquitin chain onto the yeast
APC substrates (61).
The UbcH10 N-terminus sets a threshold for APC activation by limiting the APC
activity for substrate selection and checkpoint control. Mutations of the highly conserved
UbcH10 N-terminus increase substrate ubiquitination and the number of targeted lysines
on substrates, allow ubiquitination of the APC substrates without a D-box, increase
resistance to the APC inhibitors Emi1 and MCC in vitro and bypass the SAC (spindle
assembly checkpoint) in vivo (14). These regulations guarantee that ubiquitin transfer by
the E2 won’t overcome the unmet criteria, in order to avoid the inappropriate
ubiquitination and unwanted substrate destruction.
The UbcH10 is a target of APCCdh1-mediated ubiquitination and degradation of
UbcH10 inactivates the APC. Cyclin A inhibits the auto-ubiquitination of UbcH10, but
not its E2 function. Therefore, the ubiquitination of UbcH10 will occur after high-affinity
substrates, such as Cyclins, are degraded. Because of this mechanism, the APC activity is
maintained as long as G1 substrates present (62). During G1 phase, the APC
autonomously switches to a state permissive for Cyclin A accumulation. UbcH10
accumulates at a similar time to Cyclin A in late G1 phase and is degraded in mitosis
(63). The APC is inactivated after mitosis exit.
Auto-ubiquitination of UbcH10 is regulated by a conserved N-terminal extension
of UbcH10, which is unique among E2 enzymes. The deletion of the N-terminal UbcH10
impairs the formation of ubiquitin chains by APCCdh1 but simultaneously allows some
UbcH10 ubiquitination by APCCdc20 (62). However, Pines’ group questioned the autoubiquitination of UbcH10. They reported UbcH10 didn't show a rate-limiting role in
mitosis towards APC substrate destruction. Instead they find that it is rate-limiting in late
G1 phase where UbcH10 is required to destabilize Cyclin A and prevent premature DNA
replication (63).
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Aims of the Study
The aim of this dissertation study was to gain a deeper understanding into how
APC3 recruit substrate co-receptors: Cdh1 and APC10. Therefore, I studied their
interactions through both a hybrid APC3 structure and biochemical assays. In Chapter2, I
determined the structure of the hybrid APC3 protein (a chimeric APC3) to gain further
insights into how Cdh1 and APC10 were recruited by APC3 through their highly
conserved C-terminus (IR-tails). The APC EM-derived structures of APC subunits
(APC7, APC3, APC6, APC8) were also used to check the authenticity of an interaction
model (of the IR-tails and APC3) from the structural studies. In Chapter 3, I performed
biochemical assays to understand how Cdh1 mediates the interactions with other APC
subunits. Chapter 4 serves as an overview and a discussion on the future implications of
these studies.
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CHAPTER 2. CRYSTALLIZATION AND STRUCTURE DETERMINATION OF
THE C-TERMINAL APC3: INSIGHTS INTO THE RECRUITMENT OF THE
APC CO-ACTIVATORS AND APC10 BY APC3
Crystallization Strategy
Previous studies from multiple laboratories have shown that APC co-activators
and APC10 are recruited to APC3 through their C-terminal highly conserved IR-tail
peptides (33, 34, 36, 37). It is known that the APC3 C-terminal domain is responsible for
recruiting APC co-activators and APC10, but there are no structural models to elaborate
details for the interactions. This chapter mainly focuses on the crystallographic
approaches to understand the mechanism of co-activator and APC10 recruitment by
APC3.
The crystallization attempts of APC3 full-length protein and domains +/− coactivators/APC10 have been tried and none of them succeeded. When the atomic
structure of N-terminal E. cuniculi APC3 was published (35), a strategy was developed
by us to pursue the structure of human APC3 C-terminal domain by making hybrid E.
cuniculi-human APC3 proteins. This hybrid protein idea was first reported to be a hybrid
LRR (leucine rich repeat) technique and successfully applied to crystalize human TLR4
(Toll-like receptor), a member of the LRR family (64, 65). Recently the hybrid technique
also successfully crystalized internalin B, another member of the LRR family (66). This
hybrid strategy is to facilitate soluble expression and the crystallization of the protein of
interest, by replacing an insoluble domain of the protein with a corresponding domain of
a homologue. The substitute domain is more soluble and structurally similar to the
domain that will be replaced. Similarly, the principle of our strategy is to facilitate human
C-terminal APC3 crystalization through fusing it to another protein that has a high
probability to crystalize.
Similar to E. cuniculi APC3, human APC3 is a TPR subunit with 14 predicted
TPR motifs, and N-terminal TPR1-4 mediates homo-dimerization (35). Human APC3 has
270 residues predicted disordered between TPR4 and 5, whereas E. cuniculi APC3 only
has 20 residues in the corresponding disordered region. The large disorderd region
accounts for almost 1/3 of human APC3 protein sequence and it is a hindrance to the
crystallization. In addition, human APC3 is a highly hydrophobic protein and the fulllength protein easily aggregates during in vitro purification once the affinity/stabilizing
tags are removed. The co-purification of APC3 with its co-activators or APC10 could not
prevent the protein aggregation.
In order to increase protein crystallization potential and improve protein
behaviors, two versions of the chimeric APC3 were constructed (Figure 2-1). The short
version incoporated E. cuniculi APC3 TPR5-6 and the longer version includes TPR1-6,
which includes all the crystallized domain in the published structure (35). Both versions
fused E. cuniculi APC3 TPRs to human APC3 TPR7 to 14.

22

Figure 2-1.

The crystallization strategy of the human APC3 C-terminal domain.

Illustration of the hybrid strategy to construct the chimeric APC3. The goal of the
strategy is to replace the crystallization hindrance domains of the human APC3 with
crystallizable/soluble, homologous domains of E. cuniculi APC3. Two versions of the
chimeric APC3 were generated from TPR5-6 or TPR1-6 of the E. cuniculi APC3 Nterminal domain fused onto TPR7-14 of human APC3 C-terminal domain. The long one
used N-terminal dimerization domain TPR1-4 and TPR5-6, whereas the short version
only includes TPR5-6. The expression test of APC3 domains is shown on the top right,
with each fragment fused onto a His6-MBP tag.
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Results and Discussion
The binding ability test of the chimeric APC3s
To investigate whether the chimeric APC3a are able to recruit the APC coactivators, I used a co-pulldown experiment to test its binding ability with Cdh1. The copulldown results shows that both the long and short versions of the chimeric APC3
poorly interact with Cdh1 (Figure 2-2), which implies they lost the binding abilities to
Cdh1 in solution. The co-expression of the chimeric APC3s with Cdh1 failed to restore
them to the “binding” status. The IR-tail mimicking, APC inhibitor TAME was also used
to test the chimeric APC3 binding ability via NMR WaterLOGSY. In the WaterLOGSY
experiment, a free ligand gives multiple peaks pointing downward in the spectrum. Once
the ligand binds to proteins, the peaks flipped upwards. No interaction signal with the
chimeric APC3s was observed from the TAME 1D spectra, whereas TAME binds to the
human wild type APC3 as a part of APC3-APC7-APC16 complex (Figure 2-3).
Improvement of bacterial expression of the chimeric APC3
Although the chimeric APC3s didn’t interact with the APC co-activator Cdh1, we
were still interested in knowing what caused the change to the protein function. Both
versions of the chimeric APC3 dramatically improved protein yield, solubility and
reduced the amount of aggregation from their insect cell (Hi-5) expression. Both versions
were purified through affinity chromatography, ion exchange and gel filtration, followed
by robotic crystallographic screening. The short chimeric APC3 generated hits in
conditions of 0.1M HEPEs pH7.5, 1.6MAmSO4, 2% Dioxane at room temperature
(around 25°C).
In order to determine the crystal structure of the chimeric APC3s, an experimental
phase is required to calculate an electron density map. The electron density map presents
a three-dimensional description of the electron density of the overall molecule structure
and outlines the molecule surface. A good map will make atomic model building
possible. Crystal diffraction data of high quality with phase information is key for the
crystallography software to calculate high quality maps. The phase is an intrinsic defect
in crystallography, because observed crystal diffraction is the summary of all the
electrons in the molecule. Without correct phase information, the two-dimensional
diffraction spots cannot be reconstituted back to three-dimensional coordinates to outline
the molecular envelope. Generally there are two ways to get phases: one is through
experiments (experimental phases) and the other is through homologous or predicted
models. During the structure determination of chimeric APC3, I tried varous models
from published atomic models to synthetic models, and none of them was sufficiently
accurate to generate a reasonable map. This fact indicates the chimeric APC3 structure is
significantly different than the existing models tried.
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Figure 2-2.

Test the chimeric APC3 binding ability to Cdh1 by a co-pulldown.

(a) Flow chart to demonstrate the procedure of the co-pulldown experiment to test APC3
binding ability with the Cdh1. APC3 were co-expressed with the Cdh1 and Cdh1
substrate peptide Hsl130-2xStrep in insect cell Hi-5 strain. The co-pulldown was
performed on the Strep tag of Hsl130. The amount of the APC3 co-eluted with Cdh1-Hsl30
was used to indicate their binding ability.
(b) SDS-PAGE to examine the co-pulldown results of (a). Four APC3 constructs were
tested the binding ability with both the Cdh1 full-length and WD40 domain. APC3ΔL:
Disorder region between TPRs 4 and 5 deleted. Two versions of the chimeric APC3:
human APC3 TPR 7-13 was fused with E. cuniculi APC3 TPR1-6 (long version) or TPR
5-6 (short version), respectively. FL: full-length protein. WD: WD40 propeller domain,
the Hsl130-2xStrep peptide-binding domain. Molecular weight standards are labeled on
the left side of the gel and protein bands are labeled with their names and construct
schematics.
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Figure 2-3. Examine the chimeric APC3 binding ability with APC inhibitor via
1D WaterLOGSY.
(a) Illustration of compounds TAME and AAME. Groups of each compound are
illustrated in green color.
(b) Schematic diagram of WaterLOGSY basic principle. The red rectangles and blue
triangles represent non-binding and binding ligands, respectively. Green spheres
represent water molecules. Non-binding ligands only receive magnetism transferred from
unbound water, whereas binding ligands will also receive magnetism transferred from
target proteins via bulk water molecules. In the 1D spectrum, both non-binding and
binding ligands give positive signals (upward peaks). In the WaterLOGSY spectrum, the
signals from the binding ligands remain positive and signals of the non-binding ligands
becomes negative (downward peaks).
(c,d) One-dimensional WaterLOGSY spectrum recorded of APC3 interaction with
TAME (b) and AAME (c). The three spectra from top are the protein reference spectra of
2µM chimeric APC3, 2mM Cdh1-Hsl130-Strep, and 2µM APC3-APC7-APC16, and one
compound only reference of 0.2mM compound TAME (b) or AAME (c) at the bottom.
The following three spectra from the top are the corresponding 2µM protein complexes in
the presence of 0.2mM TAME (b) or AAME (c). The spectra were acquired with 10920
scans and protein signals were destroyed with the design of WaterLOGSY pulse
sequence.
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Figure 2-3.

(Continued).
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Another common approach to obtain experimental phases is through the
diffraction that is derived from heavy atom labeled crystals. Theoretically, the covalently
attached heavy atoms will slightly shift the crystal diffraction pattern without affecting
the overall intensity. Then the crystallography software is able to calculate the map
through the anomalous signals. Selenomethionine substitution is a common way to
incorporate selenium into protein peptides and label protein crystals. The principle is to
use selenium labeled methionine to substitute normal methionine in the bacteria culture
for the cells expressing proteins to be studied. To make that method applicable, I
reconstituted the expression construct of the chimeric APC3 for bacterial expression,
followed by the expression test in various bacterial strains. In summary, the protein
could be expressed in several strains but has a 10-fold lower yield, which could not meet
the needs of the protein amount required for crystallization. In order to overcome this
barrier, different affinity tags including GST, His-MBP, GST-MBP, GST-EGFP and
GST-T4 Lysozyme, the chimeric APC3 mutants and the chimeric APC3 of different
species were used to enhance protein expression. Of the entire search, the GST-MBP tag
with the wild type chimeric APC3 increased the protein expression 5-fold in bacterial
strain BL21 gold (Figure 2-4). The final yield of GST-MBP tagged chimeric APC3 (in
vitro purified protein) was 2.6 mg per liter culture, whereas the His-MBP tagged fusion
only produced 0.55mg per liter. The purified chimeric APC3 behaves as well as the one
purified from insect cells and generated crystallography hits in a similar condition at
room temperature.
Purification improvement of seleno-methionine labeled protein
The selenomethionine (SeMet) substitution requires enriched media for bacteria
growth, which benefits the protein expression. However, the E. coli 60kDa chaperonins
were also enriched during the purification of SeMet incorporated protein. The
chaperonins accounted for 50% of final product (Figure 2-5). These co-purified
chaperonins were identified by mass spectrometry.
The chaperonins were reported to improve protein folding and they are driven by
ATP hydrolysis. ADP stabilizes the chaperonins binding to its substrates, while ATP
modifies its tertiary structure and promotes the chaperonin complex releasing the
substrates (67). The co-purification of chaperonins with the chimeric APC3 suggested
that they bind to the chimeric protein tightly. In order to separate APC3 from
chaperonins, I included two-rounds of ATP incubation during the affinity
chromatography and the incubation effectively removed the chaperonins (Figure 2-5).
The selenomethione incorporation was confirmed by intact mass spectrometry. Each
selenomethione has ~47Da more molecular weight than methione. Through comparing
the molecular weight shift between SeMet protein and native protein, 10 selenomethiones
were calculated that were incorporated into chimeric APC3 (Figure A-1).
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Figure 2-4.
MBP tag.

Bacterial production of the chimeric APC3 is improved by a GST-

The schematic map of the chimeric APC3 construct (top), and SDS-PAGE of the
chimeric APC3 protein purified from GST-MBP and His-MBP affinity tags. Proteins in
both lanes were loaded with the same amount of affinity chromatography elutions.
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Figure 2-5. ATP incubation efficiently removed Chaperonin during the chimeric
APC3 purification.
The schematic map of the chimeric APC3 construct (top), and SDS-PAGE of the purified
chimeric APC3 protein purified with or without ATP incubation (bottom). The ATP
incubation removed the E. coli Chaperonin (blue gel) that was presented in the previous
purification (gray gel). E. coli Chaperonin were identified by mass spectrometry.
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Diffraction improvement and structure determination
The diffraction of the chimeric APC3 crystals started at 8Å and it was improved
to 3Å after multiple rounds of optimization. The low resolution didn’t have enough
diffraction information to provide an accurate electron density map. A high mosacity
value was also present in the higher resolution dataset, which indicates the dataset has
multiple overlapped crystals and crystallography software could not calculate the correct
map. This problem also exists in the SeMet crystal dataset, which leads to SeMet crystal
dataset failing to generate experimental phase. Many approaches were tried to improve
the mosacity, including screening at different temperatures, new crystals forms searching
and optimization, heavy atom soaking and co-crystallization, seeding, TAME soaking,
additive screening (Table 2-1). During the optimization process, the short version
chimeric APC3 crystallized in multiple crystal forms (Figure A-2) and around 800
crystals in total from different crystal forms were harvested. All the crystals were shot at
synchrotron for data collection. Eventually, the combination of seeding, additives, and
lower temperature (18°C) helped crystals grow to more than 10 times of the original size
(Figure 2-6). The dissection of crystals into small pieces separated the overlapped
multiple crystals and a good-quality dataset was obtained for structure determination
(Figure 2-7).
The atomic structure of the chimeric APC3 was determined by means of SAD
(Single-wavelength anomalous diffraction) phasing from a SeMet dataset of 3Å. Data
collection and reﬁnement and statistics are summarized in Table 2-2.
Structural analysis of the chimeric APC3 atomic structure
The chimeric APC3 consists of 16 α-helices, with 14 of them in helix-turn-helix
(TPR) motif. Based on the structure superimposition and sequence alignment, 14 antiparallel helices are TPR5-10 and TPR12, and they match the predicted TPR motif
boundaries from APC3 secondary structure prediction from TPRpred and Psipred
(Figure 2-8a) (68, 69). Each TPR motif was then assigned to an a and a b helix, with the
a-helices lining the inner concave surface and the b-helices forming the outer convex
surface. There are two α-helices: α-11 and α-13 are not in any predicted TPR motif. The
helix α-11 is flanked by two loops and it breaks the successive TPRs pattern by folding
back to the concave surface around TPR8-10 (Figure 2-8b). α-13 is a long α-helix
following TPR12 and projects towards N-terminal TPR5. The loop-α-11-loop and α-13
are within the regions of predicted TPR11 and TPR13 domains, respectively, but neither
folds into the canonical TPR (Figure 2-8a). The TPR proteins of APC complex were
expected to form a superhelix with their consecutive TPRs as the tertiary structure (20).
However, the overall shape of the chimeric APC3 molecule does not display this
superhelix structure.
To interpret the folding mechanism, the chimeric APC3 structure was
superimposed with E. cuniculi APC3 N-terminal structure and human APC3 predicted
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Table 2-1.
Summary of optimization approaches to improve the chimeric APC3
crystal diffraction.
Approaches
Addtive screening

Description/Summary
110 additives screened

Manually seeding

120 conditions manually seeded

Robotic seedingscreening

1,300 conditions robotically screened
with crystal seeds

Heavy atoms cocrystallization

Co-crystallized with heavy atoms of
Hg, Pt, (NH4)2SeO4 and lanthanides at
1mM and 10mM
Crystals soaked with 1mM or 10mM
RT
Hg, Pt, Au, Pb, (NH4)2SeO4 and
lanthanides within pH range 6.5-7.0

Heavy atoms
soaking

Low melting (LM) Crystallization in 36 optimized
agarose growing
conditions with 1% and 2% LM
agarose
TAME soaking
20 crystals soaked in 10mM TAME
within pH range 5.5-8.5
Cryo buffer
30-40 cryo buffers tested during
screening
crystal harvest
MBP fused
Robotic screen around 1,300
chimeric APC3
conditions, followed by manual
screening with 120 additive for
optimization
T4 Lysozyme and Robotic screen around 3,000
EGFP fused
conditions
chimericAPC3
Lys-methylated
Robotic screen around 2,000
chimeric APC3
conditions
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Temp
Result
4°C & Best diffraction
RT
at 3.5Å
RT
Diffraction
around 4-5Å
4°C & Generate hits in
RT
new conditions
for optimization
RT
No crystals

RT
RT
RT
4°C &
RT

Best diffraction
at 4-5Å, but no
anomalous
signal
No crystals
Diffraction
around 4-5Å
Best diffraction
at 3Å
Diffraction
around 8Å

4°C &
RT

No crystals

4°C &
RT

Pom-pom shape
crystals

Figure 2-6. Original hits and improved crystals of the SeMet incorporated
chimeric APC3.
The crystals display the initial hits of the chimeric APC3 (left) and manual optimizated
hits (right). The initial hits grow in 0.1M MES pH6.5, 1.6M (NH4)2SO4, 10% (v/v)
Dioxane, RT. The optimization hits grew in 0.1M MES pH6.5, 1% Dioxane, 1.45M
AmSO4, 2% MPD, 0.2M MgCl2, 0.1M Li2SO4, micro seeding 1:1000 at 18°C, seeded
from native crystals.

35

Figure 2-7.

Representative electron density.

Final 2Fo–Fc electron density map contoured at σ1.4 is shown over the chimeric APC3
structure. The blue mesh represents the calculated electron density map from the
collected data and the yellow sticks indicate the peptide backbone, with oxygen atoms
labeled in red and nitrogen atoms labeled in blue (70).
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Table 2-2.

Structure data and refinement statistics of the chimeric APC3.
Statistics

Chimeric APC3 (SeMet)

Data collection
Beam line
Wavelength (Å)
Space group
Cell dimensions
a, b, c (Å)
α, β, γ (˚)
Resolution (Å)
Total reflections
Unique reflections
Rmerge (%)
Average I/σ
Completeness (%)
Redundancy
Wilson B-factor
Refinement
Resolution range (Å)
No. of reflections (σ≥0)
Rwork (%)
Rfree (%)
Number of protein atoms
Number of waters
Average B-factor (protein)
Average B-factor (water)
RMSD:
Bond lengths (Å)
Ramachandran plot statistics
Residues in preferred regions (%)
Residues in additional allowed regions (%)
Residues in disallowed regions (%)

APS 24-ID-C
0.9793
C121
a=235.5, b=130.1, c=103.9
α=90, β=110, γ=90
80-3.0
303819
111550
11.4 (75.1)
12.2 (2.0)
97.9 (75.5)
4.2 (2.1)
23.47
50-3
57195
22.24
25.49
15930
43
55.31
34.21
0.012
1.216
98.03
1.82
0.15

Highest resolution shell is shown in parenthesis. Rwork=(|Fo-Fc|/(Fo. Rfree is the
crossvalidation of R-factor, with >5% of the total reflections omitted during model
refinement.
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Figure 2-8. Analysis of the chimeric APC3 structure through sequence and
structural comparisons.
(a) Multiple sequence alignment of human APC3 homologs. The residues that match
human APC3 sequence are highlighted in yellow. Position of observed TPR motifs and
α-helix elements are labeled with salmon color, whereas predicted TPR motifs are in light
green.
(b) Superimposition of the chimeric APC3 (salmon) onto a predicted APC3 C-terminal
domain in light green. TPR8-10 superimpose closely onto the predicted model. Other
TPR motifs aligned less well with the predicted motifs in light green.
(c) Superimposition of TPR 5-6 of the chimeric APC3 structure onto TPR 5-6 of E.
cuniculi APC3 model. E. cuniculi APC3 residues 175-241, corresponding to TPR5-6
adopts identical folding in both structures.
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Figure 2-8.

(Continued).
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model, with reference to APC3 sequence comparison across eukaryotic species. The
TPR5 and 6 in the chimeric APC3 were well aligned onto their TPR5 and 6 in E. cuniculi
APC3, with an r.m.s.d of 0.5Å (Figure 2-8c), which means the TPR5 and 6 of the
chimeric APC3 kept the same folding as in E. cuniculi APC3. The following TPR7 forms
two shorter α-helices in the chimeric APC3 instead of the predicted canonical TPR7
helices. The loops following helices TPR7a and TPR7b, instead, are longer than the
prediction. Two α-helices of TPR7 spread across the concave and convex surfaces of
TPR array instead of packing parallel to TPR8 (Figure 2-8b). The sequence boundaries
of TPR8, 9 and 10 from the chimeric APC3 perfectly match their corresponding TPRs in
prediction, and two structures of TPRs 8-10 are well aligned with an r.m.s.d of 1.46Å
(Figure 2-8a, b).
One unexpected mis-folding region is helix α-11, which corresponds to the
predicted TPR11 domain but folds into a short helix, and flanked by two longer loops.
The predicted TPR11 parallel TPR10, and extends the α-helices along the TPR array to
form a superhelix. However, the helix α-11 slides into a concave surface that is lined by
the helices a of TPR 8-10 (Figure 2-8a, b). The flanking loops triple the length of a
predicted turn between two antiparallel helices. The orientation of the following TPR12
seems to be affected by the mis-folding of TPR11, although each TPR12 helix matches
the expected boundary. TPR12 is packed in a perpendicular angle to TPR10 and breaks
the pattern of the TPR arrangements (Figure 2-8b). Another affected region is the helix
α-13, which also forms within the expected TPR13 domain. α-13 adopts a long α-helix
structure rather than two short anti-parallel α-helices. α-13 is parallel to TPR12 and is
also perpendicular to TPR10. Meanwhile, the fact that α-13 extends towards TPR5 make
the overall structure a globular shape, which may explain that the chimeric APC3 have
higher solubility than most other in vitro purified APC TPR proteins.
Identify human APC3 C-terminal binding groove through model comparisons
In order to examine whether the structure of the chimeric APC3 is functional, The
Dali server was used to search structurally similar TPR proteins through threedimensional structure analysis. TPR7-12 domain of the chimeric APC3 was used as the
search model, and three hits: Carboxyl terminus of Hsp70-interacting protein (Chip), and
TPR9-11 of human APC6 and yeast APC6 all have highest structurally similarity with
human APC3 TPR8-10. All the models were superimposed onto APC3 TPR8-10 with an
r.m.s.d smaller than 1.1Å and the helix α-11 of the chimeric APC3 overlapped with all
the peptides (binding partners) of three similar hits (Figure 2-9).
The structural superimposition suggests that the highly conserved TPR8-10 in the
chimeric APC3 adopts canonical TPR protein folding (Figure 2-8a, Figure 2-10a) and
structurally it is also highly similar to three peptide-interacting domains (from the hits).
Beside, the mutagenesis study reported that the mutation (N581A/L612A of helix 8a and
9a) in this domain reduced Cdh1 association with APC with a decreased ubiquitination
(34). All the above indicate TPR8-10 is the APC3 binding groove that is responsible for
recruiting IR-tail peptides. The helix α-11 is buried inside the binding groove and

41

Figure 2-9. Structural alignments of the chimeric APC3 with TPR proteins reveal
a rigid binding groove and pseudo binding partner.
The chimeric APC3 (salmon) is superimposed onto the TPR domains of Stub1 Chip
(warm pink) and the TPR9-11 of S. pombe APC6 (olive). The cyan asterisks labeled the
interacting peptides: Hsp90 (blue) and Cdc26 (cyan), which overlapped with the helix α11.
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Figure 2-10. Pseudo binding partner α-11 interacts with two binding pockets in
the APC3 binding groove.
(a) Multiple sequence alignment of TPR8-10 motifs of human APC3 homologs. The
bars above consensus indicate the conservation strength: red, invariant residues;
orange: conserved residues. Red or orange triangle legends indicate the residues
labeled out in the model of (b). Positions of observed TPR 8-10 are labeled with
salmon color, which matched the predicted TPR 8-10 in light green.
(b) Details of conserved residues at the inner face of the binding groove model (left)
and their contribution to the surface charge (right). Left: Invariant residues are
colored in red and conserved residues colored in orange. Human Cdc26 N-terminal
peptide was superimposed onto the helix α-11 position. Right: The bar at the bottom
right indicates the surface electrostatic potential. Two binding pockets at the binding
groove surface are outlined with green (negatively charged pocket) or cyan
(hydrophobic pocket) dash lines.
(c) Close-up views of the key interactions between pseudo binding partner helix
(light-pink ribbon and sticks) and two binding pockets (surface and sticks). The α-11
residues interacting with the binding groove were displayed in pink sticks. Dotted
lines indicate the electrostatic interaction and the hydrogen bond of Lys690 with
Glu616 and Ser584, respectively.
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overlapped with all three peptides from the hits, which suggests it folds into a pseudo
binding partner for APC3 and blocked the IR-tail recruiting domain.
Human APC3 binding groove has two conserved pockets at the inner surface, one
negatively charged and the other hydrophobic
As every cloud has a silver lining, the fact that the chimeric APC3 is self-locked
by its mis-folded TPR11 implies the functionality of the binding groove. Meanwhile, the
pseudo binding partner α-11 demonstrates the interactions that the binding groove
potentially uses for recruiting IR tail peptides. Moreover, the chimeric APC3 structure
also provides a clue for studying TPR protein folding mechanism.
A sequence comparison of the APC3 binding groove (TPR8-10) reveals a striking
cluster of sequence conservation. There are 39 conserved residues among a total of 96
residues in the binding groove and 22 conserved residues locate on the inner surface
formed from α-helices 8a, 9a and 10a (Figure 2-10a). The highly conserved TPR8-10
probably is the reason that the binding groove folded correctly and independently in this
structure without being affected by the mis-folded neighbor regions.
Highly conserved residues Asn581, Leu585, Ser584, L585, Tyr608, Leu612 and
Glu616 were mapped onto the molecular surface of helices 8a and 9a, with their side
chains facing toward superimposed peptides Cdc26 (Figure 2-10b). The conserved
residues form a pocket-like surface with strong negative charges. The pocket surface
around Ser584, Glu616 is most negative. Lys690 of helix α-11 was recruited to this
pocket through electrostatic interaction with Glu616 and hydrogen bonds with Ser584
(Figure 2-10c).
The second pocket-like region within the binding groove is formed through wellconserved residues His615, Asn 642, Tyr645 and maybe a non-conserved Met649, with
their side chains facing towards the helix α-11. His615 localizes on the helix 9a and the
other three are mapped onto the helix 10a. The pseudo binding partner α-11 establishes
multiple hydrophobic interactions with the second binding pocket through Val684,
Ala687 and Leu688 (Figure 2-10c). His615 packs its imidazole group toward Ala687
and L688 of helix α-11 and the side chains of Val684 and Leu688 point to Asn642 and
Tyr645, respectively. The second pocket creates a hydrophobic microenvironment along
the concave inner face of the binding groove.
Validate human APC3 interactions with the IR-tails through mutations of the APC3
binding groove
To validate the interaction mechanism observed from the chimeric APC3
structure, key residue mutations in the APC3 binding groove were constructed and
expressed for the interaction assays. In order to have better behaviors of APC3 mutants
and Cdh1, all the mutants were expressed and purified in the complex of human APC7-
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APC3-APC16, and Cdh1 was co-expressed with its high-affinity substrate Hsl130. Similar
to the wild type APC3, all the APC3 mutants formed a stoichiometry complex with
APC7 (Figure 2-11a, bottom panel), indicating that the mutated residues did not impair
mutant interactions with APC7. Most mutants were defective in binding Cdh1 through
co-pulldown experiment (Figure 2-11a, top panel), and only three mutants,
Y608A/Y645A, H615A/Y645A and H615A/N642A/Y645A/M649A had no or opposite
effects (Figure 2-11a, middle panel).
In order to identify the most informative mutants, the WaterLOGSY was also
performed on the complexes APC7-APC3mutnts-APC16. This approach is suitable for
detecting binding affinity in the micromolar range (71), and thus it reveals more
differences of the weak interactions. In the APC3 mutant WaterLOGSY experiment, the
mutant of S584A/E616R directly affected the peaks 5 and 7, the interactions between the
backbone of Arginine side chain and the binding groove. Peaks 5 and 7 disappeared in
the mutant of S584A/E616R, and all other mutants that include these two mutations. This
result matched the speculation that S584 and E616 mediate the salt bridge with the
Arginine guanidinium group of the IR-tails (Figure 2-11b). Although salt bridge could
not be directly detected by this approach due to their higher affinity, the disappeared
interactions (of peaks 5 and 7) probably resulted from those missing interactions.
The interactions from tosyl group (Peaks 1 and 2) and from the backbone of
Arginine side chain were almost completely wiped out by another mutant of
H615A/N642A/M649A. It confirmed that the H615, N642 and M649 together form the
hydrophobic core and potentially directly interacted with the Isoleucine of the IR-tails.
Although the residues S584 and E616 were still available to mediate salt bridge, the
Arginine side chain failed to stay bound. This result indicated that hydrophobic
interactions from Isoleucine of the IR tails stabilized the salt bridge formed by the
guanidinium group.
Other mutations of the binding groove showed more or less minor binding
defectiveness towards IR-tails or TAME. The mutant of H615N/M649N lost the
interactions with Cdh1 C-terminus in the co-pulldown but only had subtle effects on
TAME (Figure 2-11a, c). However the mutant H615A/N642A/M649A became most
defective to TAME when N642A mutation was incorporated. It seemed N642 was
important for hydrophobic interactions of TAME, whereas the mutations of H615 and
M649 were enough to disrupt the IR-tail interactions. TAME were reported as an APC
inhibitor when Cdh1 was present (40, 51). Comparing to the Cdh1 IR-tail, it potentially
mediated stronger interaction with APC3.
The Y645A mutation seemed to have opposite effect on Cdh1 interaction and no
effect to TAME binding (Figure 2-11a, c). The mutants of H615A/Y645A and
H615A/N642A/M649A/Y645A tended to increased the Cdh1 interaction in the copulldowns. The function of Y645 was not certain and the mutation of Y645A might
create non-specific hydrophobic interactions.
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Figure 2-11. Mutants of key residues inside the APC3 binding groove validated
interactions between the APC3 and Cdh1 IR-tail.
(a) Co-pulldown to examine APC3 mutants binding ability with Cdh1-Hsl130-2xStrep in
the complexes of GST-APC7-APC3 (wild type or mutatns)-APC16. The co-pulldown
was performed on the Strep tag of the substrate peptide Hsl30-2xStrep (top two panels)
and GST tag of APC7 (bottom panel), separately. The top panel shows the defective
APC3 mutants and the middle panel groups three mutants of subtle or no effects. APC3
mutated residues in each co-pulldown are labeled on top of each lane, with APC3 and
Cdh1∆C as controls in the left four lanes of each gel. ∆C: IR-tail deleted Cdh1; fl: full
length Cdh1; wt: wild type APC3. All the bands marked by asterisks were identified by
mass spectrum. The red asterisks mark the bands electrophoresed from the expected
proteins. The yellow asterisk labels containment protein bands of Tublin beta-1, which
co-migrated with Cdh1fl protein through SDS-PAGE. The green asterisk indicates the
breakdown of Cdh1∆C. The spheres and triangles bellow the gels (top and middle panel)
label the positions of the corresponding APC3 mutants in the WaterLOGSY spectrum (c),
with triangles indicating the mutants of subtle or no effect towards TAME binding, and
spheres marking the defective ones.
(b) Structure illustrations of similarity of the compound TAME to the IR-tail (left),
and APC3 binding groove surface (right). The groups/residues in TAME/IR-tail are
labeled in green color, with numbers marking the corresponding proton signals/peaks
of the WaterLOGSY spectrum (c). Blue and red colors represent the electrostatic
potential of the binding groove surface as positive and negative, respectively. Two
binding centers: a negatively charged and a hydrophobic pocket at the surface are
outlined with green and cyan dashed lines, respectively. The cyan colored numbers
(1,2,6) indicate the corresponding protons potentially interact with the hydrophobic
pocket (cyan dashed lines), while the green numbers (5,7) suggest the proton signals
(of the Arginine side chain) are potentially affected by the negatively charged pocket
(green dashed lines).
(c) One-dimensional WaterLOGSY spectrum recorded interactions of the APC3 mutants
with TAME in the complexes of APC7-APC3mutants-APC16. All the spectra were
scaled with the same magnitude. Three reference spectra include the top one of 2µM
APC7-APC3wild type-APC16 with 200µM TAME and bottom two of 200µM TAME
alone, and 2µM Cdh1-Hsl130 with 200µM TAME, respectively. The ten spectra in the
middle are the 2µM APC7-APC3mutants-APC16 in the presence of 200µM TAME. The
peaks labeled out by cyan, orange and green numbers are the signals of the protons in
TAME, as labeled in (b). The cyan numbers (1,2,6) and green numbers (5,7) indicate the
binding potentially affected by the mutants in the hydrophobic pocket (b, cyan dashed
lines) and mutants in the negatively charged pocket (b, green dashed lines), respectively.
The spectra were acquired with 10920 scans and protein signals were destroyed with the
design of WaterLOGSY pulse sequence.
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Figure 2-11. (Continued).
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A hypothesis of APC3 recruiting the IR-tail and implication for future study
The helix α-11 binds to the groove through one lysine (Lys690) and one Leucine,
and they bind to two pockets with multiple interactions. Besides, these two residues are
structurally close to each other (Figure 2-10c). Lysine is structurally similar to Arginine
and Leucine is the isoform of Isoleucine. In addition, the binding pockets consist of
highly conserved residues across species, especially the negatively charged pocket
(Figure 2-10a). The sequence conservation indicates that hydrogen bonds, electrostatic
and hydrophobic interaction are evolutionarily important to bind the IR tail. Lys690 and
Leu688 of helix α-11 potentially mimic such interactions.
The first/negative charged pocket is surrounded with four conserved hydrophobic
residues: Leu585, Tyr608, Leu612, His615 and one polar residue: Asn581, mapped onto
helices 8a and 9a. Potentially they stabilize the helix α-11 in the binding groove by
contacting Leu683 and Ala687 of the helix α-11 through hydrophobic interactions
(Figure 2-10c). APC3 mutant N581A/L612A affected the hydrophobic interaction with
TAME (Ile-Arg mimic compound) mediated by Cβ, Cγ, Cδ of TAME Arg side chain. IRtail mutated to IK-tail leads to Cdh1 failing to associate with or activate APC (38). The
protonated Arginine side chain has a pKa around 12.5 whereas Lysine’s pKa is 10.5. The
positive charge of guanidino group is extensively delocalized, and it is able to establish a
stronger noncovalent interaction than Lysine.
Based on the above interaction analysis, a hypothetical model is proposed from
this study (Figure 2-12). Arginine inserts into the first binding pocket, establishing
hydrogen bonds with Ser584, and a salt bridge with Glu616. Because of the large
mobility of the Arginine long side chain, the interaction contributed from surrounding
residues Asn581 and Leu612, potentially restrict its side chain. Isoleucine is recruited to
the second binding pocket mainly through His615 and Tyr645.
Biologically, the highly conserved residues of IR tails and APC3 binding groove
indicate their interaction patterns are consistent for all species. IR tail deletion and
mutation both reduced the co-activators affinity and their ability to activate APC. The IR
tail interaction will anchor the co-activators and APC10 to the right location of APC3.
Given the orientation change of the co-activators during the APC activity regulation and
ubiquitination event (31, 32), its probably essential for the co-activators to be recruited to
the correct location before being involved in substrate recruitment and poly-ubiquitin
chain formation. The crystallographic model of APC3 with co-activators or APC10 will
provide an accurate model to understand the interaction details. Alternatively, it could
also be obtained through small compound TAME docking into APC3 binding groove,
followed by the experimental validation.
TPR subunits models docking into APC EM map
In the attempts to examine the authenticity of the APC3 binding groove model
and study the APC assembly, APC negative-stain electron microscopy maps of the
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Figure 2-12. A hypothetical model demonstrates IR-tail interacting with the APC3
binding groove.
A hypothetical model demonstrates the potential interactions between IR tail (green and
cyan sticks) and APC3 binding groove (surface and sticks), with oxygen and nitrogen
atoms of labeled residues in red and blue, respectively. The surface charge is identical as
shown in Figure 2-10b. Dashed lines label the interactions of the salt bridge and
hydrogen bond.
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recombinant human APC and human APCCdh1-Emi1 (EMD 2226 and 2354) (23, 72)were
used for generating TPR subunit models. The Itasser predicted models of TPR subunits
and APC1 were used to initiate model docking (73). N-terminal and C-terminal domains
of each TPR subunit model were docked in separately. The N-terminal TPR motifs
mediate dimerization and they were docked in as a dimer (instead of monomers). The
TPR1-4 of both APC3 and APC7 form homodimers, whereas the N-terminal 6 TPR
motifs (TPR1-6) mediate larger dimers of APC6 and APC8. The TPR4 and 5 of APC3
are separated by a disordered loop of about 270 residues, and the loop has no matched
density on both EM maps. Moreover, the loops or short α-helices of each model were
deleted if there are no matched densities. The binding groove of the chimeric APC3
model agrees with the APC3 C-terminal predicted model with a superimposition r.m.s.d
of 1.46Å (Figure 2-6a, b). Therefore, it is incorporated into the APC3 C-terminal
predicted model for docking.
The correlation coefficients of models generated from EM map docking are listed
in the Table 2-3. EMD 2354 (23) is the map of complex APCCdh1-Emi1 and EMD 2226
(72) is from the APC sample without Cdh1. The coordinates of human APC10 and Yeast
Cdh1 propeller domain were used as references and they both have higher correlation
coefficients of 0.89 and 0.92, respectively. The high correlation coefficients between
docked models and their corresponding densities of the EM maps indicate a good fit
between the TPR models and the EM map.
EM-derived dimers of APC7, APC3, APC6 and APC8 dimerize through their Nterminal domains and generate “V” shape molecules of all the APC TPR subunits
(Figure 2-13). Each dimer has a unique overall shape with angles and dimensions
different from others. APC3 dimer has a mamxium dimension of 135 Å. Although there
is a 270-residue loop separating TPR4 and 5, APC3 TPR motifs together with α-helices
between TPR4 and 5 adopt a linear superhelix measuring 110 Å in length and 40 Å in
diameter.
All the prediction models are based on protein crystallographic or homologous
modeling. N-terminal domains of human APC3 and APC6 are predicted based on the
yeast APC6 atomic model (PDB code: 2XPI), whereas the human APC8 dimerization
domain is based on the yeast APC8 structure (PDB code: 3ZNZ). The EM-derived
dimerization domains of APC3 and APC6 have 0.4Å and 0.8Å deviation with their
homologus model (yeast APC6), respectively, and APC8 N-terminal domain deviates
around 0.4Å from the yeast APC8 structure. The atomic structure of human APC7 TPR13 has been determined (PDB code: 3FFL), although the dimerization interface of the
structure is biologically irrelevant. The model of APC1 PC repeats are predicted from
26S proteasome subunit Rpn2, and its overall structure looks like a closed toroid of two
concentric α-helical rings. The PC repeat consists of tandem copies of 35-40 amino acid
repeat motifs, with each motif forming into α-helix-turn-α helix.
TPR 1-4 of the EM-derived APC3 model were superimposed onto the
corresponding TPRs of APC6, E. cuniculi APC3 and APC8 structures with r.m.s.d of
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Table 2-3.
maps.

Correlation coefficients of EM-derived TPR structures to APC EM

The models of EM docking
APC7 N-terminal dimer (TPR1-4)
APC3 N-terminal dimer (TPR1-4)
APC6 N-terminal dimer (TPR1-6)
APC8 N-terminal dimer (TPR1-6)
APC7 C-terminal domain (TPR5-C)
APC3 C-terminal domain (TPR5-C)
APC6 C-terminal domain (TPR7-C)
APC8 C-terminal domain (TPR7-C)
APC1 PC repeats
APC10 (PDB code: 1JHJ)
Cdh1 (PDB code: 4BH6)
Cdh1 with substrate KEN box and D box
(PDB code: 4BH6)

Correlation
coefficient in
APCCdh1-Emi1 EM
map (EMD 2354)
0.87
0.8865
0.8983
0.8415
0.8337
0.8706
0.8311
0.8507
0.8452
0.8951
-
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Correlation
coefficient in APC
EM map (EMD
2226)
0.859
0.8868
0.9043
0.862
0.8745
0.858
0.8926
0.7949
0.8131
0.8905
0.9182
0.9242

Figure 2-13. TPR subunits form elongated V-shape homo-dimers in the human
APC assembly.
APC7, APC3, APC6, APC8 all form “V”-shaped homo-dimers and assemble in parallel
in a hierarchical fashion to build the arc lamp (TPR arm) of the human APC. All the
models are predicted by Itasser and adjusted based on the APCCdh1-Emi1 EM map (EMD
2354) (23). The more globular dimerization modules form the apex of the ‘V’, and the
narrower C‐ terminal TPR superhelices project away from the dimer interfaces.
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0.6Å, 2.2Å and 1.8Å, respectively. Additionally, the TPR1-4 in APC3 and APC7
structure (PDB code: 3FFL) are 2.8Å deviated from each other (Figure A-3). The first
four TPR motifs in all EM-derived structures all adopt canonical folding and are similar
to each other. The following secondary structures, TPR5-6, has different orientation and
helix length among four TPR subunits and could not be aligned (Figure 2-14a, b). The
C-terminal TPR motifs make the differences among V-shape dimers of four TPR subunits
(Figure 2-13).
All the TPR subunit dimerization domains localize at the backside of APC
complex, where all TPR proteins assemble into the TPR arm. The atomic fitting of the
TPR subunits to the EM map accounts for the major density of the TPR arm (more than
90% of the density), and rationalized its repetitive layered architecture. Two copies of
APC3 TPR5-14 spiral along two opposite directions to the front side of the APC, where
Cdh1 and APC10 contact APC3 (Figure 2-14c). Each co-receptor (Cdh1 or APC10) is
attached to one copy of the C-terminal APC3, respectively. In the EM-derived structures
of the APC3 C-terminal TPR5-14, TPR8-10 is contributed from the chimeric APC3
atomic model. All the α-helices present in the predicted models match the secondary
structure prediction (Figure 2-6).
Although the C-terminal IR tail peptides of both Cdh1 and APC10 atomic
structures are absent, EM maps demonstrate additional electronic densities which extend
from the C-terminal end of APC10 β-barrel folds. The densities connect APC10 to the
APC3 binding groove TPRs (TPR8-10) and it ends at the docked IR-tail model inside the
groove (Figure 2-14d). Potentially these densities are contributed from the C-terminal
peptides of APC10. The distance between APC10 model C-terminus and Ile of the IR-tail
model is around 30-40Å, and 20 residues of C-terminal APC10 will be more than enough
to bridge this distance.
Implication of the C-terminal APC3 alternative folding
The chimeric APC3 self-lock is an interesting phenomenon during the protein
folding. In order to explore the mechanism that accounts for this phenomenon, the APC3
sequence flanking the binding groove was analyzed through the comparison between
EM-derived model and the chimeric APC3 model in the corresponding domains. For
most canonical TPR proteins, the packing between α-helices requires intra-helices
interaction (20, 26, 27, 35, 37). In the EM-derived model, five residues —Val676,
His680, Ile681, Val683 and Val684 — of the helix 11a (TPR11a) are involved in
mediating such intra-helices interaction (Figure 2-15a, left) with the hydrophobic
residues Tyr, Phe and Leu of TPR10. These hydrophobic interactions maintain the helix
11a packing in parallel to TPR10. However, this canonical folding pattern is disrupted in
the chimeric APC3 model (Figure 2-15a, right), where residues Val683, Val684, Ala687,
Leu688 and Lys690 interact with the binding groove and mediate the formation of the
helix α-11.
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Figure 2-14. Models of TPR subunits docked into the negative-stain EM map of
the human APCCdh1-Emi1 complex.
(a, b) The comparisons of EM-derived N-terminal models (TPR1-6) of human APC3,
APC6 and APC8, with E. cuniculi APC3 N-terminal structure (a, PDB code:
3KAE)(a) and S. pombe APC8 N-terminal model (b, PDB code: 3ZNZ). The αhelices are displayed with the shapes of cyclinders in (b).
(c) Two stereo views showing the APC models closely fit in the molecular envelope
of APCCdh1-Emi1 complex (EMD 2354) (23).
(d) Details of the interactions between APC3 and C-terminal APC10. The model of
human APC10 is used for docking, with a red asterisk indicating its C-terminal end.
The hypothetical IR tail interaction model (Figure 2-12) is incorporated into the EMderived APC3 structure, and together they are docked into the APCCdh1-Emi1 EM map.
The model of the IR tail is showed as cyan sticks, with the interacting residues
labeled in red and orange sticks as showed in Figure 2-11. The black arrow points at
the density contributed from APC10 C-terminal unstructured peptides, with the dot
line representing its possible orientation. The red asterisk indicates C-terminal end of
APC10 β-barrels. The corresponding APC10 sequence to the labeled density is
marked out with dotted lines at bottom. The unstructured C-terminal peptides of
APC10, Cdh1 and Cdc20 all have similar number of residues.
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Figure 2-14. (Continued).
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Figure 2-15. The binding groove of human APC3 affects TPR11 adopts a canonical
folding.
(a) Views of TPR11 folding in EM-derived model (left panel) and the chimeric APC3
structure (right panel). The binding grooves (TPR8-10) are presented as surface density.
Purple labeled residues mediating TPR11 packing in parallel with TPR10 (left) while
they are in a disordered loop in chimeric APC3. Pink color denotes the residues that
theatrically stabilizing the TPR11a (left) but mediating α-11 formation in the chimeric
APC3 (right).
(b) Multiple sequence alignment at TPR10-11 motifs of human APC3 orthologs. The
blue bars above consensus indicate lower conservation strength than the red and orange
bars. (Red, invariant residues; orange: conserved residues). The purple and pink
diamonds denotes the residues that are colored or labeled out by sticks (with the same
colors) in (a). Position of the chimeric APC3 TPR 10 and α-11 are colored in salmon, and
TPR10 and 11 in EM-derived APC3 model are labeled in green.
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It is important to understand what triggers TPR11 folding into a pseudo binding
partner instead of a canonical TPR motif, since no literature reports APC3 or TPR protein
self-lock phenomenon. The sequence of APC3 TPR11 shows it is relatively less
conserved compared to the sequence of other APC3 C-terminal TPR motifs (Figure
2-15b, Figure 2-10a, Figure 2-8a). This may suggest that this region is less stable in
adopting the canonical TPR motifs. Meanwhile, the fact that TPR11 folds into another
helix (α-11) inside APC3 binding groove also indicates that the binding groove is capable
of mediating strong hydrophobic interactions. Combining the above two aspects together,
it seems human APC3 needs assistance from other domains or proteins to maintain
canonical TPR protein folding.
In addition to non-canonical folding of TPR11, TPR7 in the chimeric APC3
structure doesn’t keep canonical folding either. Instead it folds into a short helix-long
loop-short helix secondary structure. The EM-derived APC3 model provides a clue to
interpret the mechanism of the human APC3 canonical folding. The TPR7 of the EMderived model is parallel with TPR6b. To study the factors that leads to this alternative
folding, the interaction between TPR6 and TPR7, and protein sequence comparison are
examined. The stereoviews of canonically folded TPR6 and 7 from the EM-derived
model display the interactions between them (Figure 2-16a). The packing of helix 7a
(TPR7a) to the helix 6b (TPR6b) is mediated through four conserved residues R532,
F528, E525, Y521 of the helix 6b, with one residue assigned to one turn of the helix and
lined up to face towards TPR7a (Figure 2-16a, left). Two of the four conserved residues:
Arginine and Phenylalanine are the same as the E. cuniculi APC3 TPR6b at the
equivalent positions (Figure 2-16b). The other two residues, Glutamic Acid and
Tyrosine, potentially stabilize the helix 7a through hydrogen bonds with Threonine (T548
of TPR7a) and hydrophobic side-chain interactions with Histidine and Leucine (H551,
L552) at the last turn of the helix 7a. However, Glutamic Acid and Tyrosine (E525,
Y521) are not present in the TPR6 of E. cuniculi APC3. The disrupted interactions
potentially cause the lost the canonical TPR folding of the helix 7a. Instead it becomes a
loop in the structure, with Histidine and Leucine (H551, L552) exposed in the solvent
(Figure 2-16a, right).
Unlike the TPR11, there is no other contact to TPR7 from other helices inside
APC3 or other subunits of APC (demonstrated through EM map docking). It seems that
TPR7 adopts correct folding in a TPR6-dependent manner, and TPR7 requires the whole
set of conserved residues from its neighbor helix to stabilize its correct secondary
structures. The sequence of both TPR7 and TPR11 are less conserved than those of the
binding groove. Without the correct stabilizing interactions around TPR7, it forms into
two shorter helices within the TPR motif boundary instead of a canonical α-helix-turn-αhelix motif (Figure 2-16a).
Biological meaning of APC3 folding and implication to future study
The protein superhelical conformation was first discovered in Phosphatase 5 and
it is believed to coordinate multi-subunit assembly (74). The canonically folded APC3
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Figure 2-16. Human APC3 TPR7 folds in a TPR6-dependent manner.
(a) Two stereoviews to demonstrate the interaction between the helices TPR6b and
TPR7a in the EM-derived APC3 model (left), and the corresponding but disrupted
interactions in the chimeric APC3 model (right).
(b) The cross-species comparison of sequence corresponding to the TPR6 motif of APC3.
Red residues are conserved in both the human and E. cuniculi APC3; orange and blue
residues vary. The yellow highlights mark residues identical among different species.
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adopts the right-handed superhelical structure. The superhelix makes it possible to
establish new contacts among sequence distant helices.
It is also interesting that the independently folded APC3 binding groove is flanked
by two TPR motifs (TPR 7 and 11) whose secondary structures are sensitive to the
proceeding TPR motifs and/or the tertiary structure. The human APC3 seems to require
the whole C-terminal TPR domain (TPR5-13) to adopt and maintain the canonical
folding. APC3 itself is located in a highly hydrophobic microenvironment (the TPR arm)
that is created from all other TPR subunits. The inner surface of the binding groove is
encircled by the superhelix of TPR5-11, which potentially repel unexpected helices
interacting with the binding groove but keep the groove accessible for the unstructured IR
tail peptides, or small molecules like TAME. Given that APC3 is sandwiched in the TPR
arm by another two subunits: APC7 (top) and APC6 (bottom), it is probably critical to
prevent the nonspecific interactions (from unexpected α-helices) locking the binding
groove. Similar to APC3, APC6 also localizes in the hydrophobic microenvironment, and
C-terminal superhelices of APC3 and APC6 have similar dimensions (Figure 2-17). The
C-terminal APC6 accommodates the N-terminal peptide of Cdc26, which is the key to
stabilize APC6 superhelical structure (26, 27). The APC3 superhelix potentially limits the
space around the binding groove surface and this limited space is more accessible to
peptides or small compounds than α-helices.
Although the crystallographic model of the chimeric APC3 adopts a self-lock
structure, it reveals reliable surface details of human APC3 binding groove, for further
recruitment mechanism study. The self-lock structure also partially displays the binding
groove mediated interaction. Being incorporated by the chimeric APC3 structure, the
EM-derived model becomes a guide for further assay design to validate interactions of
APC3 with the co-activators and APC10. This information could also benefit APC
inhibitor, like the compound TAME, optimization to improve their affinity to the binding
groove. Additionally, this model provides clues that allow speculation the role of APC3
tertiary structure in maintaining its function.
Crystallization attempts of APC TPR subunits
Crystallizations of other APC TPR subunits were tried (approached), as listed in
Table A-1. It includes the complex of the full-length proteins APC8-APC6-Cdc26 from
different species, and a truncated APC3 in the complex of APC3∆L-APC16 with or
without Cdh1. The full-length complex APC8-APC6-Cdc26 didn’t crystallize, but the
APC3∆L-APC16 crystallized with or without Cdh1 (Figure A-4, Figure A-5). Both
crystals showed the optimization potential by diffracting to 6Å and 7Å, respectively.
Until the time this dissertation is written, they are still being pursued.
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Figure 2-17. The superhelix structure limits the accessibility of the APC3 binding
groove.
Structural superimposition of S. pombe APC6 (yellow, PDB code: 2XPI) and EM-derived
human APC3 (green) demonstrates that two structures have similar dimensions of
superhelices. The docked IR tail model is showed as a cyan stick. Both IR tail and Nterminal Cdc26 are buried inside the groove of the superhelices.
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Materials and Methods
Constructs for crystallization
All the protein expression constructs were made by standard PCR/ligation
procedures, and sequences were verified by automated sequencing procedures. The APC3
deletion and mutation were designed with reference to the human APC3 830 a.a sequence
isoform (uniprot code: P30260). The E. cucniculi APC3 sequence used for designing the
APC3 chimeras refers to the reported one in (35) (uniprot code: Q8SQV4). The TPR7-14
of the human APC3 refers to residues 539-830 of the full-length protein. TPR1-6 of E.
cucniculi APC3 refers to residues 1-241 and TPR 5-6 refers to 175-241 of the parasite
APC3 sequece. The chimeric APC3s were cloned to an N-terminal His6-MBP- tagged
insect or bacterial expression vector, and a GST or GST-MBP tagged bacterial vector.
The crystallization tags, including an enhanced green fluorescent protein (EGFP),
a T4 lysozyme and a MBP-(AAA), used for crystallizing the chimeric APC3s were
inserted between the N-terminal GST tag and the chimeric APC3. The EGFP residues
1-230 were used for crystallization (uniprot code: C5MKY7), and the T4 lysozyme
(uniprot code: P00720) was linked to the N-terminus of the chimeric APC3s with three
Alanines residues, similar to the MBP-(AAA) tag. The MBP-(AAA) is the crystallization
version of a maltose binding protein (PDB code: 3RUM_A). Alternative APC3 chimera
constructs were the TPR7-14 of two yeasts and a worm APC3 fused to the E. cuniculi
APC3 TPR1-6 and TPR5-6, respectively. The TPR7-14 of different species refers to the
residues: S. pombe 397-665 (NCBI code: NP_594604.2), S. cerevisiae 506-758 (uniprot
code: P38042), C. elegans 527-788 (NCBI code: NP_001021714). The chimeric APC3
mutant refers to the mutations of V181K and I185D of the E. cuniculi APC3.
The Cdh1 truncation and deletion constructs have been described in the Material
and Methods of Chapter three. The human Cdh1, Cdc20 and APC10 C-terminal peptide
(also named the IR-tail peptides) constructs were made by the above cloning procedure.
The Cdh1 IR-tail peptide refers to the residues 479-496. Protein sequences of the human
Cdc20 and APC10 are referred from Uniprot (uniprot code: Q12834, Q9UM13). The
APC10 IR peptides have two versions: residues 161-185 and 171-185. The Cdc20 IR-tail
peptides include residues 474-499. All of the peptides were fused to an N-terminal GST,
His6-MBP-, and GST-MBP-(AAA) within the bacterial expression vectors.
The bacterial expression vectors for the N-terminal GST-, His6-MBP-, GSTMBP, or His6- fusions were from either a regular or modified version of pGEX4T1 (GE
lifesciences), pRSF1b (Novagen) vectors. The insect cell expression vectors for the above
fusions were constructed from the vectors pFastBac1, pFastBac-GST, and modified
pFastBac-His6MBP (Invitrogen).
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Protein expression and purification from bacteria
The E. coli expression strains, BL21(DE3) Gold (Novagen), codon enhanced RIL
(Stratagene) and Rosetta (Novagen) were used for expression tests of the protein
constructs. Most of the large-scale protein production from the bacteria was done in
BL21(DE3) Gold, with the cells cultured in LB broth Miller (EMD) supplemented with
the appropriate antibiotics.
The chimeric APC3 proteins were expressed from the bacterial vector pGEX-4T1
(GE). The starter media was incubated at 37°C overnight in a rotary shaker at 200
revolutions per minute (rpm). The overnight culture 10 ml was then used to inoculate into
12L LB media that contains a final concentration of 200 μg/ml ampicillin. The
BL21(DE3) Gold strain harboring the expression constructs were cultured at 37°C until
reaching an OD600 of ~0.8. After cooling the media to 18°C for 1hr, the expression was
induced by the addition of IPTG (isopropyl β-D-1-thiogalactopyranoside) to a final
concentration of 0.6 mM, followed by overnight culture at 18°C. The next day, the cells
were resuspended in a buffer of 50 mM Tris-HCl pH7.6, 0.3 M NaCl, 5 mM DTT, and
supplemented with 2.5 mM PMSF, and lysed by sonication on ice. The GST-MBP tagged
chimeric APC3s were purified by glutathione-affinity chromatography, and eluted protein
fractions were treated with the homemade TEV protease at 4°C overnight at 1:50 ratio.
The cleavage by TEV protease left 2 extra residues (Gly-Ser) on the N-terminus of
proteins prior to the protein linker Glu-Phe-Ser-Gly.
For co-crystallization, the chimeric APC3s were purified by Ion Exchange
chromatography (IEC) to separate the cleaved affinity tags from the purified proteins,
based on the isoelectric point difference. IEC is done with a 5ml Hi-Trap column (GE) in
a buffer of 50mM Tris-Cl pH 8.0, and the protein fractions were concentrated to 2040mg/ml (Bio-Rad Protein Assay), followed by a gel filtration chromatography. The gel
filtration was performed to further remove contaminants based on the molecular shapes
and sizes, using a Superose 6 column (GE) in a buffer of 50 mM Tris-HCl pH 7.6, 0.3 M
NaCl and 5 mM DTT. After gel filtration, the remaining GST-MBP and uncleaved
chimeric APC3 protein were removed with glutathione-affinity resins before the purified
protein was concentrated to 20-25 mg/ml (A280 measured), aliquotted, flash-frozen in
liquid nitrogen, and stored at -80°C until latter use.
The Selenomethionine labeled chimeric APC3 was expressed in the BL21(DE3)
Gold cells cultured in the autoinduction media. The cells grew in a 24L-culture at 37°C
till they passed the exponential phase and then the temperature was reduced to 18˚C
overnight for protein production.. The SeMet incorporated protein was purified through
GST chromatography. Before the 10mM glutathione elution, a wash buffer containing
25mM ATP was incubated twice with protein-bound glutathione sepharose/resins for 15
mins/per wash, followed by the additional resin wash to remove the extra ATP. The
elutions of the SeMet chimeric APC3 were applied the same purification procedure as the
native protein. Following size exclusion chromatography, the protein was concentrated
and stored in a buffer containing 50 mM Tris-Cl pH 7.6, 300 mM NaCl and 5mM DTT.
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The protein concentration used for crystallography varied within the range of 12.5-25
mg/ml (A280 measured).
Crystal screening and optimization
Crystallograhy screenings were performed using a Mosquito crystallization robot
(TTP Labtech) with the commercial 96-well screens. Over 2,000 commercially available
and homemade conditions were screened at 4°C and room temperature (RT), and one
initial hit was found two days later in needle shaped clusters. This hit grew in the
condition of 0.1M MES pH6.5, 1.6M (NH4)2SO4, and 10% (v/v) Dioxane at RT. All the
robotic screening used the hanging drop vapor diffusion method against 100μl of well
solution with a drop ratio 1:1 (200 nl protein: 200 nl well solution), with a protein
concentration of 15-20mg/ml.
To improve crystal size, manual screenings were performed using the ratios of
1:1, 1:2 and 2:1 (1ul:1μl or 2ul:2ul, 1ul:2ul, and 2ul:1µl protein:well solution). Crystal
drops were equilibrated by vapor diffusion against 500 μl-1ml of precipitant solutions at
RT. Meanwhile, I optimized the screening around the initial conditions with different
precipitant concentrations, different pH buffers, and different commercial and homemade
additives under different temperatures, combining with the streak and micro seedings.
The optimization screenings were summrized in the Table 2-3. The optimized condition
of 0.1M MES pH6.5, 1.8M (NH4)2SO4, 2% (v/v) Dioxane and 2% MPD tripled the
crystal size. Multiple rounds of cryo buffer screenings were performed to obtain qualified
diffractions. More than 50 cryo buffers of 23 cryoprotectants were screened, and the best
cryo-buffer is a buffer of 0.1M MES 6.5, 10% Dioxane, 1M AmSO4, and 6.5M Amformate.
Another attempt to obtain high quality diffractions was to search new crystal
forms. Around 1,000 commercial conditions were used as additives (10% commercial
conditions +90% the optimized hit condition) and also as new precipitants (90%
commercial +10% the optimized hit condition). MPD was screened out as a new
precipitant that supports crystals rapidly growing larger (the crystals grew across a drop),
in either long needle shaped clusters or thin plates. The optimized conditions of 0.1M
MES 6.5/ 0.1M HEPEs pH 7.0/ 0.1M Bicine pH 8.0, 0.2M AmSO4, and 48-51% MPD
generated SeMet and native crystals with a length of ~0.4mm and in a shape of longneedles or thin-quadrilaterals. Interestingly, the larger crystals were dehydrated and
quickly dissolved within two minutes when exposed to the air. The flash-frozen crystals
in the drop solution (50%MPD is a cryoprotectant) diffracted to 4Å but in an anisotropic
diffraction pattern (a diffraction pattern of stripes instead of lunes).
The further attempts focused on improving the diffraction quality of the SeMet
crystals. The solution failed to be calculated at the beginning because of the complexity
that is contributed from both 70 Selenium sites inside one asymmetric unit (ASU) and the
overlapped crystal lattices. The streak seeding, macro-seeding and lower temperature (to
slow down crystals growing) didn't help the crystals grow single. Eventually the single-
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lattice dataset was collected from a small crystal (~0.2mm) that was gently dissected
from a 0.4mm long/large crystal, growing in the condition of 0.1M MES pH6.5, 1%
Dioxane, 1.45M AmSO4, 2% MPD, 0.2M MgCl2 and 0.1M Li2SO4, micro seeded from
native crystals in a ratio of 1:1000 at 18°C.
During the phase information pursuit, alternative approaches including heavy
atom co-crystallization and soaking were also applied. The co-crystallization is
performed manually by setting the screenings with the mixture of the protein and heavy
atoms. The soaking is to soak native crystals in different heavy atoms, combined with the
optimization of crystallization or cryo buffers, temperatures and wash times to remove
the background heavy atoms. The soaked crystals were harvested for data collection at
APS (Advanced Photon Source) and ALS (Advanced Light Source), and collected
diffraction data were used for the heavy atom incorporation analysis.
Crystallization of the chimeric APC3 modified by reductive methylation
Reductive methylation was applied to improve the solubility of the chimeric
APC3 through dimethylation of all the surface-exposed lysines (75, 76). In order to get
the complete methylation, the purified chimeric APC3 was thawed and dialyzed in a
buffer of 50mM HEPEs pH7.5, 0.3M NaCl and 5mMDTT to replace the protein storage
(Tris) buffer. Freshly prepared 1M dimethyl amine borane complex (DMAB) and 1M
formaldehyde were gently added into the protein solution, with the amount of 20µl
DMAB per ml protein and 40µl formaldehyde per ml protein. This mix was gently
repeated once and the protein was incubated at 4˚C for 2 hours to be methylated. Then a
final aliquot of 10µl DMAB per ml protein was added into the mixture to methylate the
protein overnight. The methylation mixture was gel filtrated the next day with a
Superose6 column in a buffer of 50mM Tris-Cl pH7.6, 0.3M NaCl, 5mMDTT to quench
the reaction and remove the excess DMAB and formaldehyde. The elution was examined
by SDS-PAGE and then was concentrated to 12.5-25 mg/ml (A280 measured), aliquots,
flash-frozen in liquid nitrogen, and stored at -80°C. In order to confirm the protein
methylation, one aliquot of the frozen protein was analyzed with Intact Masspectrometry
to detect the protein mass changes contributed from the methyl groups. The chimeric
APC3 had 6-7 Lysine methylated based on the Intact Masspectrometry results.
The purified Lys-methylated protein was thawed on ice and robotic screening of
the protein was performed with the commercial 96-well screens. Around 1,000
commercial conditions were screened at 4°C and RT, respectively. One initial hit was
generated in the condition of 0.1M CAPS pH10.5 and 40% MPD at 4°C. The following
optimization was performed through robotic and manual screening, but the crystallization
couldn’t be optimized.
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Crystallization of the T4 Lysozyme, EGFP and MBP-(AAA) fused chimeric APC3
Robotic screenings were performed on the T4Lysozyme, EGFP and MBP-(AAA)
fused chimeric APC3. The proteins were concentrated to 15-20mg/ml (A280 measured)
after the purification from the affinity chromatography, ion exchange and size exclusion
chromatography. For each protein, 2,000 of total commercially available conditions were
screened at 4°C and RT. Only the MBP-(AAA) fusion was found two hits in the
conditions of 0.1M BTP pH7.5, 20% PEG3350, and 0.2M NaI or KSCN. The MBP(AAA) fusion mixed with maltose of a final concentration of 1mM before screening. The
crystals grew in a shape of small rods (shorter than 0.1mm) or small plates. The
PEG3350 of a serial of concentrations in the pH 6.5-8.5 was manually screened with the
0.2M additives of NaI or KSCN, using 96-well homemade blocks. The best
crystallization buffer turned out to be Tris-Cl pH7.5. More additives screenings were
performed using the commercial additive screens, and 20 additives out of all positive hits
were further screened manual (with the original hit condition) to optimize the crystal size.
The crystals grew into the shape of longer rods (0.1-0.2mm) or rhomboids, and were
harvested for data collection at Argonne national laboratory (APS), but no crystals
diffracted.
Data collection
The diffraction datasets of high quality were collected at APS, 24-ID-C. The
dataset was indexed into a space group of C2, and integrated and scaled with HKL2000.
A fluorescence scan was performed prior to data collection (to another crystal) to
determine the peak energy/wavelength for Selenium. The dataset was collected at single
wavelength of λ= 0.9798Å with an exposure time of 0.5 seconds per frame, and a 0.5
degree oscillation angle for 360 degree collection. The single-wavelength anomalous
dispersion (SAD) benefits the low anomalous signals to be detected and scaled.
For heavy atoms screening, both the SAD and multiple-wavelength anomalous
dispersion (MAD) were applied. A few fluorescence scans prior to data collection were
performed to detect the heavy atom incorporation and optimize the collection strategy.
The profile of the scans would provide the readouts of the absorption vector f’’,
dispersion vector f’ and the collection wavelengthes for MAD.
Solution and phase determination
The crystallographic structure program phenix.autoso was used to generate the
solution of the collected dataset and phase the chimeric APC3 structure, through a
process of automatically determining the Selenium positions, calculating and refining the
phases, and finally generating an electron density map. The scale file of the input for
Autosol was from HKL2000 and included the information of a space group (C2), unit cell
parameters, redundancy (2.2), wavelength (0.9798Å) and the scattering factors (f' -8.0
and f" 4.5). In order to obtain enough information for the solution calculation, the
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collected dataset was initially scaled at 2.8Å with a lower Isigma/error of 1. Autosol
found 70 out of 72 expected Selenium sites and 58 sites have higher than 0.5 occupancy
scores. In spite of a marginal value of 0.34 of the figure of merit (FOM, the marginal
range is 0.25 - 0.45), the abundant heavy atoms sites provided a relatively strong phase,
and leaded to a continuous experimental map with the clear solvent boundaries. The
initial map has a deviation value (skew) of 0.16 at electron density distribution.
Structure refinement
The initial structural model of the chimeric APC3 was built de novo in the
program Autosol, with poly-Alanines modeled in the initial experimental map, followed
by the protein sequence docking into the peptide chains. A refinement procedure was
automatically initiated after docking and generated a refined map with a built-in model.
The initial model has an Rfree of 0.30. This was followed by repeated cycles of manual
model building in Coot (70). Then the side chains were placed into the autosol refined
experimental map, and large errors from the initial models were manually fixed. The
iterative refinement was performed with phenix.refine (77). The refinement aimed at two
cycles of xyz coordinates, real-space, global non-crystallographic symmetry (NCS)
restraints, and automatical Asn/Gln/His errors correction. Those refinement parameters
are all suitable for diffraction of moderate resolution (lower than 2.5Å). R-free dropped
from 0.3 to 0.28, which is calculated from randomly selected five percent of all the
independently measured reflections to prevent the artifact errors introduced by models.
The refined 2Fo-Fc and Fo-Fc Fourier maps, combining with the ramachandran
constraints were used for correcting the model errors from the side chains and backbones.
The optimization of x-ray term/stereochemistry and x-ray ADP were incorporated
into the following 3 cycles of refinement, and 70 water molecules were added/updated to
the structural model (with the minimal resolution of 3.2Å). The refined model containing
the newly added water molecules was manually checked after the 3 cycles of refinement.
Residues of the model and the water molecules that have less than 30% occupancies were
removed or side-chains truncated before the final refinement cycle. The final cycle of
refinement of the chimeric APC3 was carried out with water molecules by minimization
refinement (occupancies) and individual B-factor refinement, resulting in an Rwork and
Rfree of 22.24% and 25.49%, respectively. All the statistic details of the refined structure
are available in Table 2-2.
The Ramachandran plot was generated to check the main-chain torsion angles of
structure model by program Coot (78). The Ramachandran plot has 98% of residues in
the most favored region and 0.15% in the disallowed region.
Co-pulldown assays
The binding capacity tests of the chimeric APC3 to Cdh1 were performed through
the insect cells Hi-5 in vitro expression. The chimeric APC3s (both long and short

69

version) were fused to a N-terminal His6-MBP tag and cloned to the insect cell
expression vector pFastBac. Both the full-length APC3 and APC3ΔL constructs were
tagged with the GST tags. The constructs of Cdh1 and Cdh1WDΔC refer to the full-length
protein and Cdh1 residues 162-462, respectively. Both these constructs were tagged with
a N-terminal 3Myc-His6 and the Myc tag refers to a peptide sequence of NEQKLISEEDL-C. Hsl130 refers to yeast Hsl1 residues 770-790 fused to residues 818842, and together this sequence reconstitutes the substrate KEN and D-box motifs, which
are recognized by the APC co-receptors. Hsl130 was tagged with a N-terminal twin strep
tag (two copies), and each strep tag consists of residues N-WSHPQFEK-C. All the
sequences of these constructs were verified by DNA sequencing.
The pFastBac constructs were then transformed into the competent cells of E. coli
EMBacY strain (79), which generated the recombinant Bacmids (a baculovirus shuttle
vector) to carry the genes for co-pulldown experiments. The transformed competent cells
were cultured in 1ml Super Optimal Broth (SOC) media at 37°C for 6hrs before they
were plated onto LB-agar plates containing 100µg/ml ampicillin, 50μg/ml kanamycin,
10μg/ml tetracycline and 7μg/ml gentamycin. All the LB-agar plates were supplemented
with 100μg/ml Xgal and 40μg/ml IPTG in advance to enable the lacZ blue-white
selection to identify the white colonies being incorporated with the gene of interest. The
white colonies were re-streaked onto fresh plates with the same supplements and
incubated at 37°C for another day. The colony-PCR valued positive colonies were
amplified overnight for preparing Bacmid DNA. The over-night culture medium kept the
same antibiotics as the LB-agar plates.
After cells were harvested from the over-night cultures, the cell pellets were
resuspended in 300μl of Qiagen buffer P1, lysed by addition of 300μl of Qiagen buffer
P2 at room temperature for five minutes and recovered on ice for ten minutes by
incubating with another additional 300μl of Qiagen buffer P3. The precipitation was
pelleted at room temperature by centrifugation at 13,000rpm for 10 minutes. The cleared
lysate 700μl was added to 800μl of ice cold isopropanol and incubated for 5 minutes on
dry ice. The precipitated Bacmid DNA was pelleted at room temperature by
centrifugation at 13,000rpm for 10 minutes and the pelleted DNA was washed with 70%
(v/v) Ethanol. The clean Bacmid DNA was resuspended in 50μl of sterile elution buffer
(Qiagen) inside a laminar flow hood (sterile conditions).
Insect cell Sf9 was used to produce and amplify the baculovirus of infection.
Bacmid DNA 1-2µg were diluted into 100µl serum-free media and then mixed with 10µl
of FuGene HD transfection reagent. The transfection mix was then incubated at 27°C for
30 minutes before being diluted by 1ml serum-free medium. The diluted mix was then
added into a 6-well plate that is freshly coated with 2×106 healthy Sf9 cells and was
incubated with Sf9 cells at at 27°C for 6 hours. After transfection, another 2ml of serumfree medium was added back into the Sf9 cells for continuous incubation for 4-5 days at
27°C. The baculovirus were harvested when infected Sf9 cells began to produce green
fluorescence signal (under UV excitation). The harvested virus was the 1st generation and
it needed to be amplified for another two rounds before infection. The virus was
amplified in 25mm cell culture dishes with each dish freshly coated by ~20×106 healthy
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Sf9 cells. Each amplification mix was made by mixing 500µl of 1st generation virus with
5ml of serum-free medium and then the mix was added into 25mm dishes before
incubation at 27°C for 2 hours. After 2 hours, another 15ml of serum-free medium was
added into each dish for 3-day incubation at 27°C before 2nd generation of baculovirus
was harvested. The 3rd generation of baculovirus was prepared with the same procedure.
Co-infections were performed on Hi-5 insect cells at a density of 10-20×106
cells/ml by adding the 3rd generation of baculovirus. The infected cells were cultured at
27°C for 2 hours at a speed of 120 revolutions per min (rpm) and then followed by
incubation at 20°C for 2 days. The co-infection was set up in 200ml for each copulldown, and the baculorvirus used for infection was kept at the ratio of 1:100 (the
volume of viruses: infection). The infected Hi-5 cells were harvested and cell pellets were
resuspended in a buffer of 50mM Tris-HCl pH7.6, 0.2M NaCl and 5mM DTT (wash
buffer), supplemented with 10ug/ml Aprotinin, 5ug/ml Leupeptin, one tablet of the
protease inhibitor per 50ml of the wash buffer (Sigma) and 2.5 mM PMSF, and lysed by
sonication on ice. The lysates were spun at 4°C twice, at 15,000rpm for 20 minutes and
then the supernant were incubated with strep-tactin sepharose (IBA) on a rotary shaker at
4°C for 1 hour. Half-milliliter slurry of the strep-tactin beads (0.25ml) was used for each
co-pulldown. The protein-bound strep beads were then washed twice with two beadvolume of the wash buffer before loading on the column, followed by a column wash
with 20 bead-volumes of the wash buffer. The proteins of each co-pulldown were
eventually removed from the beads with an elution buffer of 50mM Tris-HCl pH7.6,
0.2M NaCl, 5mM DTT and 2.5mM dethiobiotin, and each elution was examined by SDSPAGE.
The models of the APC subunits docking in the APC EM maps
Human APC10 model (PDB code: 1JHJ) was used for docking in APC10 density
with the N-terminal 9 residues removed from the atomic coordinates. The N-terminal
loop (9 residues) has no matching density in both EM maps, EM2226 and EM 2354. The
density of the Cdh1 propeller domain was docked with S. cerevisiae Cdh1 molecular
model (PDB code: 4BH6), with the coordinates of the Cdh1 inhibitor Acm1 removed.
The coordinates of the inhibitor KEN box and D-box were kept with the Cdh1 docking
model. The WD40 propeller domains of the human and yeast Cdh1 had a high sequence
identity of 49%. All the models for the EM map docking are originally predicted by Itasser server (73). The TPR7-14 of the human APC3 was modeled based on the atomic
model of human Acetyl-Glucosaminyl Transferase (PDB code: 1w3b) with an overall
sequence identity of 17%. The TPR1-6 of APC3 was modeled based on S. pombe APC6
molecular model (PDB code: 2xpi) with a 15% sequence identity. The other TPR
subunits, APC7, APC6 and APC8 are all modeled from S. pombe APC6 structure, with
the sequence identities of 15%, 36% and 18%, respectively. The crystallographic models
of human C-terminal APC6 and N-terminal APC7 were incorporated into the
corresponding docking models, respectively (PDB code: 3HYM, 3FFL).
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All the model docking were performed through the software Chimera (80). The
model editing and superimposition were done through COOT (81) and Pymol (82). Each
model was manually docked into the corresponding density of the APC EM maps with a
potential orientation, followed by the optimized local fitting through Chimera “fit in
map” function, which adjusted the orientations of the filled models based on the
calculated correlation coefficients. The docking was repeated through multiple rounds of
iteration process including model re-editing and repeated docking till the most reasonable
and/or the best fitting was achieved. The N-terminal and C-terminal coordinates of all the
TPR subunits were docked in separately. After docking, each EM-derived structure was
calculated for the correlation related to the EM maps.
The editing of the docking models was also guided from the model
superimpositions. The superimposition of each model was adjusted with reference to the
sequence comparisons of the APC subunit orthologs, and the 2nd structures corresponding
to the same TPR motifs were manually aligned together in Coot.
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CHAPTER 3. INTERACTION STUDY OF THE CO-ACTIVATORS WITH APC3,
APC8 AND THE APC PLATFORM
Introduction
During the cell cycle, APC co-activators Cdh1 and Cdc20 are recruited to the
complex through their C-terminal highly conserved IR-tails (33, 34, 36, 37). Whereas on
the APC scaffold, the homo-dimeric TPR subunit APC3 is responsible for the coactivator recruitment. Cdh1 and APC10 also function as substrate receptors. APC
substrates are recruited between Cdh1 and APC10 in a D-box (destruction motif)
dependent manner. D-box is a common sequence within substrates that allows the APC to
identify the substrates. An APC EM study revealed that Cdh1 and APC10 are connected
through the substrate D-box once the substrate is bound (31, 32), although APC10 itself
has weak affinity to substrates. Moreover, the ratio of co-activators and APC10 is
maintained at 1:1 in an active APC complex.
Besides IR-tail mediated interaction, Cdh1 and Cdc20 were also found to have
multiple interactions with the APC, and together these interactions generate high-affinity
binding of the activator to the APC core. Cdh1 interacts with another TPR subunit, APC8
at C-terminal unknown sites (34) and also with APC2, since the removal of APC2 leads
to reduced Cdh1 association (18). Cdh1 substrate-recruitment domain, the WD40
propeller, also shows some weak interactions with APC3 (33). It is likely that the highaffinity interactions keep activators bound during multiple substrate-binding of
ubiquitination events (34).
The TPR subunits APC3 and APC8 both have 14 TPR motifs, with N-terminal
TPR1-4 mediating TPR subunit dimerization. The study of APC recruiting co-activators
will help understand the APC ubiquitination mechanism and APC activity regulation
during the cell cycles.
Results and Discussion
Cdh1 binds to APC3 mainly through its C-terminal IR-tail peptide
In order to understand the recruitment mechanism of activators to APC, I
reconstituted the interaction in vitro between the activators and APC3 or APC8. It was
shown by previous lab members that most APC subunits could not be expressed in E. coli
strains, and thus an insect cell expression system was chosen to perform experiments in
this chapter. One approach used to investigate their interaction is co-pulldown assays.
Principally, I co-expressed the various proteins fused with GST, Strep, His-MBP affinity
tags in insect cells and detected their interaction through affinity purification, followed by
examination of the purified products through SDS-PAGE (Figure 3-1a).

73

Figure 3-1.

Human Cdh1 binds to APC3 and APC8 in vitro.

(a) Schematic representation of co-purification/co-pulldown procedure.
(b) Left: SDS-PAGE co-pulldown result of the GST-Cdh1 and APC3 (left), Cdh1 and
GST-APC8 (right) from insect cell co-infections. All the bands labeled were identified by
mass spectrometry. Molecular weight standards are labeled on the left side of the gel.
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In vitro purified Cdc20 and APC10 behave poorly; therefore, Cdh1 was used for
all the interaction studies in this chapter. Previously, the interactions of Cdh1 with APC3
and APC8 were tested by co-pulldown from Hi-5 insect cells. APC3 and APC8 could be
co-purified with Cdh1 (Figure 3-1). GST (Glutathione S-Transferases) affinity tag was
used for this experiment. Although the stoichiometry between APC3, APC8 and Cdh1 are
not 1:1 in this initial experiment, the results demonstrated that the association between
APC3 or APC8 and Cdh1 were reconstituted in vitro. Cdh1 expression was previously
shown to be very impure, characterized by a lot of contaminants associated during
purification (Figure 3-1b, left). Compared to most other subunits of the APC, APC8
expressed relatively well by itself. The unequal stoichiometry is probably because the
GST-tagged proteins expressed better than the un-tagged binding partners (Figure 3-1b,
right).
The co-pulldown experiments of Cdh1 with APC3 and APC8 were optimized
through two strategies. One is to improve Cdh1 behavior by co-purification with yeast
APC substrate peptide Hsl130 and the other strategy is to perform a co-pulldown on the
twin-Strep tag that was fused to the Hsl130 C-terminus. Hsl1 is a yeast APC substrate and
it associates with Cdh1through its D-box (destruction box) and KEN box motif (83, 84).
The D-box and KEN-box are the sequence elements inside most APC substrates that bind
to the Cdh1 WD40 propeller domain. The Cdh1 WD40 domain functions as a D-box and
KEN box receptor (33). Hsl130 is a shorter version of Hsl1 that only contains its D-box
and KEN-box. The substrate peptide stabilizes Cdh1, making it behave better. The copurified Cdh1-Hsl130 has less associated contaminants and adopts more homogenous
conformations based on Cdh1 purification experiments from previous lab members.
In order to explore the ability of each Cdh1 domain to interact with APC3, the
Cdh1 protein sequence was analyzed and serial deletions of Cdh1 were constructed for
co-pulldown experiments (Figure 3-2a). The activator Cdh1 has similar structure
domains/motifs: C-box, WD40 propeller and C-terminal IR tail peptides as Cdc20. Nterminal Cdh1 was serially truncated towards the WD40 domain in units of 20 amino
acids, and the C-terminal IR tail peptide was also deleted. The N-terminal 160 residues of
Cdh1 without the WD40 domain are not able to bind substrate Hsl130 by themselves
(Figure 3-2b). Except the Cdh1N160 pulldown, which was performed on the twin-strep tag
of APC16, all other co-pulldown experiments were performed on the twin-strep tags of
the Hsl130.
To improve the behavior of human APC3, APC3ΔL substituted for the full-length
protein for the experiment. APC3 is a highly hydrophobic protein due to its high α-helix
content. The full-length protein aggregates in the absence of stabilizing partners. APC3
has a large disordered loop between TPR 4 and 5 and deletion of that region — APC3ΔL
effectively limits the aggregation. The disordered loop was discovered as a highly
phosphorylated region (85) and it mediates the APC3 interaction with APC7. APC16 was
recently identified as a small subunit of the APC to stabilize APC3 association with
APC7 (86). APC16 binds to both APC3 and APC3ΔL, and the disordered loop of APC3
has no contribution towards binding with APC16 (Figure 3-2b).
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Figure 3-2.

Map human Cdh1 domains required to interact with APC3.

(a) Illustration of the domain mapping strategy for APC3ΔL, Cdh1 co-pulldown
experiments. APC3 is represented in a green parallelogram, APC16 in a red sphere and
Cdh1 in a blue octagon, with their construct schematics listed below. A GST affinity tag
was fused to the APC3ΔL N-terminus and a Strep tag was fused to the Hsl130 C-terminus.
Each co-expression had the protein components of APC3ΔL, APC16, Cdh1(full length or
truncated)
, Hsl130. Strep tagged APC16 was used for the APC3∆L co-expression with
Cdh1N160 and the non-tag APC16 was used in the other co-expressions. Human Cdh1
constructs included C-terminal IR peptide deletion (∆C), a serial of N-terminal truncation
(∆20-140, residues number) and N-terminal fragment 1-160. WD40 domain is the Cdh1
substrate-binding region. Insect cell Hi-5 strain was used for co-expression and the
experiment was performed on a Strep tag.
(b) SDS-PAGE of purified product from APC3ΔL, Cdh1 co-pulldown experiments.
Protein loading for each lane was normalized to Cdh1. Molecular weight standards are
labeled on the left side of the gel, and the protein bands on the gel were labeled with their
names and their schematic illustrations.
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Cdh1 deletions were well expressed in insect cells (Hi-5 strain) and all the
deletions were pulled down by Hsl130-Strep except Cdh1N160. Compared to the deletion
of Cdh1 IR tail peptide, the N-terminal deletions mildly affect Cdh1 interaction with
APC3ΔL (Figure 3-2b). The amount of APC3ΔL co-purified with N-terminal deletions
dropped down to half the amount of APC3ΔL co-pull down with full-length Cdh1.
Without the C-terminal IR tail, APC3ΔL could barely interact with Cdh1. This result
matches literature reports that the Cdh1 IR tail is critical for mediating APC3 interaction
(37). There was no significant difference among the co-pulldowns from Cdh1 N-terminal
deletions, which could be because co-pulldown assays are not sensitive enough to
differentiate weak interactions.
To compensate for the limitation of co-pulldown assays and also to measure the
kinetics of APC3 and Cdh1 interaction, other approaches including ITC (Isothermal
Titration Calibration), SPR (Surface Plasmon Resonance) and native gel shift assay were
applied. APC3, APC3ΔL and Cdh1 only behave well under the experimental conditions
of native gel shift assays (4°C), but not at room temperature. The interaction between
APC3 and Cdh1 did not produce a significant thermal change to be measured through
ITC. The native gel shift assay is able to detect nM binding affinities of protein-protein
interactions under native conditions through a polyacrylamide gel. It turned out to be the
approach that produced detectable results in this study. The interacting protein pairs have
a different mobility on PAGE compared to the non-binding proteins in the control.
Except Cdh1N160, all other Cdh1 deletions used for native gel shift assay were copurified with Hsl130 from double affinity tag chromatography, followed by gel filtration.
APC3ΔL-APC16 is purified and stored as a 1:1 stoichiometric protein complex and this
complex forms a band on the native gel at pH 8.2, 4°C (Figure 3-3b). All the Cdh1Hsl130 complexes and Cdh1N160 were unable to electrophorese into native gels because of
their basic pI value. Therefore, the gel shift experiment was designed to detect the band
shift of the APC3ΔL-APC16 complex.
No APC3ΔL-APC16 band was detected in the presence of Cdh1FL-Hsl130,
indicating that all the loaded APC3ΔL-APC16 (in vitro purified complex) was bound to
Cdh1. When Cdh1Δ140-Hsl130 interacts with APC3, APC3ΔL-APC16 runs as a smear on
the native gel instead of a band or disappearance. It might be because the conformation of
APC3ΔL-Cdh1 complex is different when the Cdh1 N-terminal 160 residues are missing.
Cdh1’s N-terminal 140 residues by themselves don't shift the APC3ΔL-APC16 band on
the gel. It seems that N-terminal Cdh1 is not necessary to mediate the interaction with
APC3 although the co-pulldown experiment showed less APC3ΔL bound to the Nterminal deletion.
Cdh1ΔC-Hsl130 also demonstrates some weak interactions with APC3 in this
approach, which could be contributed from the WD40 propeller domains. The WD40
propeller domains of yeast Cdh1 were observed to have multi-site weak cross-linking
interactions with APC3, and C box also has a one site weak-interaction with APC3 (33).
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Figure 3-3.

Identify Cdh1 binding domains to APC3.

(a) Illustration of experimental procedure for the native gel shift assay. APC3 is
represented in a green parallelogram, APC16 in a red sphere and Cdh1 in a blue octagon,
with their construct schematics listed below. Purified proteins or protein complexes were
used for the experiment. The protein complexes APC3ΔL-APC16 and Cdh1(full length or
truncated)
- Hsl130-Strep were purified separately from insect cell Hi-5 expression. Cdh1N160
was purified by itself without Hsl130-Strep. Beside a full-length construct used for this
asaay, human Cdh1 constructs also included C-terminal IR peptide deletion (∆C), a Nterminal 140 residue truncation (∆140) and N-terminal fragment 1-160. WD40 domain is
the Cdh1 substrate-binding region.
(b) Native gel shift to examine the interaction between APC3ΔL and Cdh1. The control
lanes are marked with an orange line at the bottom of the gel and the experimental lanes
are marked with a green line. APC3ΔL-APC16 was mixed with Cdh1-Hsl130-Strep (full
length or truncated) at a 1:10 molar ratio and incubated on ice for 20 minutes before
loading. 21µM APC3ΔL-APC16 was used as a control and for each mixture. The protein
complex band on the gel was labeled with its name and a schematic illustration.
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Study of the IR-tail APC3 interactions via an IR-tail mimicked compound
The compound TAME is designed to inhibit APC activity by mimicing the IR tail
structure of activators Cdh1, Cdc20 and co-receptor APC10, which all interact with
APC3 through their C-terminal highly conserved IR tail. TAME disrupts the activator
association with APC and inhibits the APC activity (40, 51). TAME uses a tosyl group to
mimic Ile, and it also has a methyl ester group on the Arg carboxyl.
The interaction between TAME and APC3 protein complexes were detected by
WaterLOGSY (water-ligand observed via gradient spectroscopy). The experiments were
performed at room temperature after proteins were mixed with TAME in pH 7.0
phosphate-buffered saline (PBS) with 10% D2O. In WaterLOGSY experiments, the
interacting ligands receive magnetization transferred from bulk water via the water
molecules buried in binding pockets and labile protein protons, through the mechanism of
NOEs (Nuclear Overhauser Effect) and chemical exchange. The experiments are
designed to achieve efficient selective water excitation, which tends to detect the signal
from interacting ligands by inverting the water signal (71, 87). The intensity of nonbinding and tight binding ligands are characterized as negative amplitudes and those of
weak interacting ligands are positive. For the tight binding ligands, the negative intensity
results from either less water molecules inside unfilled binding pockets or a slower
proton-exchange rate.
During any WaterLOGSY screening, the solvent signals (~5ppm) were
suppressed to limit the artifacts in the spectrum. The peaks in this experiment were
distributed from 1.5ppm to 7.5ppm. The downward peaks from the compound reference
spectrum are signals from free ligands — non-binding TAME. The corresponding peaks
of waterLOGSY spectrum inverted (upwards) in the presence of APC3 protein complex
imply the interactions between APC3 and TAME. TAME specifically binds to APC3
complexes but not to Cdh1-Hsl130, and each peak was assigned to a proton of TAME
according to their ppm value (Figure 3-4a).
WaterLOGSY is a sensitive approach to detect relatively weak interaction
between proteins and ligands. Signals indicating weak interaction have positive
amplitude in the spectrum. Peaks one to four and peak six of the experimental spectrums
revealed weak interaction between TAME and APC3, which were not affected by APC3
mutant and APC3ΔL (disorder loop deletion) (Figure 3-4b). Four of the interactions are
contributed by tosyl protons and one is from methyl protons (Figure 3-4a). Meanwhile,
peak five and seven pointed downwards in the spectrum of wild type APC3 with TAME,
and they inverted upwards in the spectrum of APC3ΔL and APC3mut. Peak five and
seven were the proton signal of the Arg group, and therefore the inversion indicated the
Arg interaction with APC3mut or APC3ΔL is weaker than with wild type APC3. Peak
three was detected in the spectrum of APC3 complexes with TAME but not in the
compound reference spectrum. It is probably because the signal from proton three is very
subtle if TAME is the free ligand in solution. Combining all the peaks in the three
experimental spectrums, I can see that TAME interacts with APC3 with its tosyl group,
Arg group and methyl easter, with the Arg group binding relatively tighter than the other
two.
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Figure 3-4.

Compound TAME mimics the IR tail interactions with APC3.

(a) Structure illustration of compound TAME and IR tail. Groups are illustrated in green
color.
(b) One-dimensional WaterLOGSY spectra record of APC3 interaction with TAME. The
five spectra from the top are the reference spectrum of three APC3 complexes (2µM
each), 2µM Cdh1-Hsl130-Strep complex and 0.2mM compound TAME. Another four
spectra from the bottom are the corresponding 2µM protein complexes in the presence of
0.2mM TAME. The peaks labeled out by orange and blue arrows are the signals of the
protons in TAME, with the same set of numbers as in (a). The peaks labeled out with
blue arrows indicate stronger interactions than those with orange arrows. The spectra
were acquired with 10920 scans and protein signals were destroyed with the design of
WaterLOGSY pulse sequence.
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The mutated residues of APC3 are the residues that are conserved in the APC3
binding groove (Figure 2-10), which have been reported to reduce the association of
Cdh1 with APC (34). The NMR WaterLOGSY results showed N581A/L612A decrease
the affinity of the Arg (of the IR tail) to APC3 but do not completely disrupt the
interaction. Given ten conserved residues of the binding groove surface potentially
mediate IR tail recruitment, the mutation of two residues is probably not sufficient to
eliminate the interaction. APC3ΔL has no mutation in the binding groove but still has a
similar defect as the APC3 mutants. The wild type APC3 of the APC3-APC7-APC16
complex appears to have better overall structure to stabilize the interactions with the IR
tails.
APC8 interacts with N-terminal Cdh1
APC8 has similar aggregation behavior as APC3 if it is purified by itself. The
strategy to solve the aggregation problem is to co-purify it with APC13 and APC6-Cdc26
complex. APC6 is an APC TPR subunit and it requires Cdc26 to fold into the correct
conformation (26, 27). APC6 associates with APC8 tightly in vitro. APC13 is a small
subunit that promotes the stable association of APC6 and APC3 to the APC complex
(25), originally identified in yeast. Human APC13 also binds to APC8 in vitro but could
not rescue APC8 alone from aggregation. Therefore, APC6-Cdc26 and APC13 are both
used to stabilize APC8.
Compared to the interaction between APC3 and Cdh1 in their co-pulldown
experiment, APC8 turned out to be a much weaker interacting partner for full-length
Cdh1 (Figure 3-5). The Cdh1 N-terminal deletions appeared defective in pulling down
APC8, and the difference among all the deletions also became indistinguishable.
Nonetheless, the N-terminal Cdh1 showed a greater propensity towards binding APC8
over APC3.
To identify the Cdh1 binding domains to APC8 and compare the results to the
interactions between Cdh1 and APC3, the same set of Cdh1 deletions were used for
native gel shift assays. It appears that Cdh1 is able to bind to the APC8-APC6 complex
only when the N-terminal 140 residues are present, and the interaction disappears when
the N-terminal 140 residues were deleted (Figure 3-6). However, those N-terminal
residues alone could not interact with APC8 if they are expressed/purified by themselves
(without the WD40 domain).
The APC8-APC6-Cdc26-APC13 complex for native gel shift assay is prepared
through affinity chromatography on the GST affinity tag fused to APC8, followed by ion
exchange chromatography and gel filtration. These gel shift results are reproducible.
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Figure 3-5.

Map human Cdh1 domains required to interact with APC8.

(a) Schematic illustration of the domain mapping strategy for APC8, Cdh1 co-pulldown
experiments. APC8 and APC6 are represented in a pink and a yellow parallelogram,
respectively, with APC13 and Cdc26 separately shown in a cyan and a light-blue sphere.
Cdh1 is demonstrated with a blue octagon, and the schematics of all the constructs used
for the co-pulldown are listed below. Human Cdh1 constructs included C-terminal IR
peptide deletion (∆C), a serial of N-terminal truncation (∆20-140, residues number) and
N-terminal fragment 1-160. WD40 domain is the Cdh1 substrate-binding region. A GST
affinity tag was fused to the APC8 N-terminus and a Strep tag was fused to the Hsl130 Cterminus. APC8, APC6, APC13, Cdc26, Cdh1(full length or truncated), and Hsl130-Strep were all
co-expressed in insect cell Hi-5 strain. The experiments were performed on a Strep tag
except the one with Cdh1N160, which was performed on a GST tag.
(b) SDS-PAGE of purified product from APC8, Cdh1 co-pulldown experiments. Protein
loading for each pulldown was normalized to Cdh1. Molecular weight standards are
labeled on the left side of the gel, and the protein bands on the gel were labeled with their
names and their schematic illustrations.
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Figure 3-6.

Identify Cdh1 binding domains to APC8.

(a) Schematic illustration of constructs used for APC8, Cdh1 native gel shift experiments.
Purified proteins were used for the experiment. APC8 and APC6 are represented in a
pink and a yellow parallelogram, respectively, with APC13 and Cdc26 separately shown
in a cyan and a light-blue sphere. Cdh1 is demonstrated with a blue octagon, and the
schematics of the constructs used for the assay are listed below. Human Cdh1 constructs
included C-terminal IR peptide deletion (∆C), a N-terminal truncation of 140 residues
(∆140) and N-terminal fragment 1-160. WD40 domain is the Cdh1 substrate-binding
region. The protein complexes APC8-APC6-APC13-Cdc26 and Cdh1(full length or truncated)Hsl130-Strep were purified separately by co-expression in insect cell Hi-5 strain. Cdh1N160
was purified by itself without Hsl130-Strep.
(b) Native gel shift to examine the interaction between Cdh1 and APC8 with APC8 as
part of the APC8-APC6-APC13-Cdc26 complex. The control lanes are marked with an
orange line at the bottom of the gel and the experimental lanes are marked with a green
line. The APC8 complex and Cdh1(full length or truncated)-Hsl130-Strep were mixed on ice for
20 minutes before loading. 18µM APC8-APC6-APC13-Cdc26 was used in both the
control and in each mixture. The molar ratio of Cdh1(full length or truncated) to APC8 complex
is 10:1. The protein complex band on the gel was labeled with its name and a schematic
illustration.
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The interaction of N-terminal Cdh1 with the APC platform
N-terminal Cdh1 is predicted to fold into α-helices (by Psipred, Figure A-6) (68)
and the corresponding densities are identified towards the inside of the APC. But the
molecular envelopes of all the published EM maps are not clear/detailed enough for the
N-terminal secondary structure assignment. The APC quaternary structure displays both
the APC8 and APC1 repeats are connected with N-terminal Cdh1 by strong densities
(Figure 3-7a). The green spheres mark the corresponding mutation in APC8 (N339A)
that was reported to reduce yeast Cdh1 association to APC in vivo (34). The APC
topological structure displays the APC8 mutation is in close proximity to N-terminal
Cdh1 density, suggesting it mediates interactions between these two subunits. The
disruption to the interaction of APC8 with Cdh1 begins with Cdh1 N-terminal 20
residues deletion, and N-terminal 20 residues are predicted to form two α-helices (Figure
3-5b, Figure A-6). It implies that the N-terminal 20 residues of Cdh1 contact APC8.
To test the interaction between Cdh1 and other APC subunits (mainly platform
subunits), more native gel assays were performed (Figure 3-7b). The recombinant APC
platform, which includes all the non-TPR subunits, appeared as a clearly visible band on
a native gel with or without APC8-APC13. The clear bands from the native gel indicate
that the majority of the complexes have a rigid and homogenous conformation. The same
set of Cdh1 deletions from APC8 and APC3 binding test were used for the assay.
The full-length and C-terminal peptide deleted Cdh1 both bind to APC8/APC13
+/− platform (Figure 3-7b). The interaction disappears without N-terminal Cdh1 (before
WD40 domain). The gel shift patterns are similar to the ones of the APC8 TPR complex
interacting with Cdh1 (Figure 3-6b). Cdh1(fl or Δ140) attached to the APC8-APC13platform forms a shifted band on the gel, whereas the majority of the Cdh1(fl or Δ140) platform disappears or becomes a smear. This may mean the Cdh1(fl or Δ140) -platform has
a more flexible conformation without APC8-APC13. The interaction between APC8 and
Cdh1 might stabilize the association of Cdh1 with other platform subunits.
Same as the native gel shift results of Cdh1 with APC8 and APC3, the
recombinant N-terminal fragment of Cdh1 did not show any interaction with either
platform complex. There could be many explanations for this. The Cdh1 N-terminal
fragment seems to have flexible folding, and half of the fragment is predicted to be a
disordered loop (Figure A-6). The EM-derived N-terminal helices only cover 60% of the
fragment sequence and other residues of the disordered loops could not be identified
through the current EM maps. One possibility is that the Cdh1 N-terminal fragment will
fold accordingly once it comes in contact with the APC platform subunits.
Implication of Cdh1 N-terminal interactions
The amounts of co-activators bound to APC are rate-limiting for ubiquitination
reactions (88), and therefore it is important and interesting to understand how coactivator association supports APC ubiquitination activity. Multiple previous studies
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Figure 3-7.

N-terminal Cdh1 interacts with the APC platform.

(a) Human APC architecture demonstrated by EM-derived structures and APC4APC5 EM map (yellow mesh, EMD 1843) (89) docked into the corresponding
densities on the APC EM map (EMD 2354) (23). The locations of APC2 and APC11
are annotated as a yellow circle and the APC platform is outlined with a red dash line.
The model of the N-terminal Cdh1 includes a bunch of α-helices extending towards
the inside of the APC (left). The green spheres indicate the corresponding APC8
residue that decreased Cdh1 association with the yeast APC (32). The blue circle
mark the localization of the density contributed by the N-terminal Cdh1, with two
close views demonstrating the interactions of N-terminal Cdh1 with APC8 and APC1
PC repeats.
(b) Native gel shift assays to identify the Cdh1 domains required for APC8 +/−
platform interaction (top, middle panels), with GST-ubiquitin as an interaction control
(bottom panel). The control lanes in each gel are marked with an orange line at the
bottom of the gel and the experiment lanes are marked with a green line. APC8 +/−
platform or GST-ubiquitin were mixed with Cdh1(full length or truncated)-Hsl130-Strep,
respectively, on ice for 20 minutes before loading. 5µM APC8-platform, 3.8µM
platform and 37µM GST-ubiquitin were used as controls and for each mix. The molar
ratio of Cdh1 (full length or truncated) to APC8 +/− platform or GST-ubiquitin is
10:1. The protein complex band on the gel was labeled with its name and a schematic
illustration.
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Figure 3-7.

(Continued).
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showed that the attachment of Cdh1 to APC is stabilized by multiple interactions, which
likely supports that Cdh1 binds when ubiquitinated substrates are released from the APC
(18, 34).
The interactions between APC3 and the IR-tail peptides of the co-activators or
APC10 have been well characterized by biochemical and structural approaches, although
their atomic details remain unknown. In contrast, the Cdh1 association to other APC
subunits is still not well understood. In addition to the reported interactions of Cdh1 with
APC being confirmed in this chapter (18, 33, 34, 37), the EM-derived structures are also
incorporated to shed light on revealing the mechanism. Potentially, the N-terminal Cdh1
helices interact with APC8, APC1 PC repeats and APC4-APC5
Given that the disordered regions of N-terminal Cdh1 couldn’t be identified
through the EM map, biochemical assays will be required to determine the binding details
between the Cdh1 N-terminal regions and the platform subunits. To characterize the role
of the N-terminus of Cdh1 in the multi-interaction, more thorough Cdh1 N-terminal
deletions/mutations would be required to test binding with the APC platform,
recombinant APC1-APC4-APC5, and in vitro purified single platform subunits. Since
APC2-APC11 couldn’t form a visible band in a native gel, this approach is not applicable
for the catalytic subunits. Meanwhile, the crystallization of the APC platform with Cdh1
would be an alternative approach to reveal the details of their interaction.
Human Cdh1 is subject to phosphorylation in vivo by Cdks (Cyclin-dependent
kinases), and the Cdk-dependent phosphorylation sites are responsible for blocking the
APC interaction with Cdh1. APCCdc20 inhibits the recruitment of Cdh1 to the APC by
phosphorylating Cdh1 until the latter stages of mitosis (88, 90). The majority of the
phosphorylation sites are at the N-terminal fragment (before the conserved WD40
domain) (85, 88), and therefore, phosphorylation interrupts Cdh1 binding to APC. In
vitro, phosphorylated Cdh1 binds to or activates the APC less efficiently when compared
to non-phosphorylated Cdh1, whereas non-phosphorylatable Cdh1 mutants constitutively
activate APC in vitro and in vivo (90). Combining the effects from Cdh1 phosphorylation
with the data on Cdh1’s multi interactions with the APC may further elucidate the
mechanism of how Cdh1 association regulate APC activity.
Materials and Methods
Constructs and insect cell infection
Protein expression constructs were made by standard PCR/ligation procedures,
and sequences were verified by automated sequencing procedures. The APC3 deletion
and mutation were designed in reference to the human APC3 830 a.a sequence isoform
(uniprot code: P30260). The disordered region of residues 182-453 were deleted for
APC3ΔL, and APC3mut refers to APC3 with Asn581 and L612 both mutated into Ala.
The APC16 construct includes the full-length protein sequence of APC16 (uniprot code:
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Q96DE5), and APC1674 refers to residues 74-110. The constructs of APC8, APC6,
Cdc26 and APC13 also used the full-length protein sequence (uniprot code: Q9UJX2,
Q13042, Q8NHZ8 and Q9BS18). Human APC8 refers to the isoform with 597a.a. For
the chimeric APC3, there is a long version and a short one. The long version fused the Nterminal residues 1-241 of E. cuniculi APC3 to Human APC3 residues 539-830. The
short one used the E. cuniculi residues175-241 to fuse to Human APC3 residues 539-830.
Hsl130 was made by cloning yeast Hsl1 residues 770-790, which includes a KEN box,
and residues 818-842, which includes a high affinity D-box, into the substrate peptide.
Human Cdh1 has 496a.a. (uniprot code: Q9UM11). Cdh1ΔC refers to the last 17 residues
deleted from the C-terminus, and Cdh1Δ20-140 means the corresponding number of
residues deleted from N-terminal Cdh1. The Cdh1 WD40 propeller domain includes
residues162-479, and the C box refers to residues 45-52.
All the constructs described in this chapter were expressed using the Bac-to-Bac
baculovirus expression system (Invitrogen). The sequences-verified pFastBac constructs
were transformed into E. coli DH10B or E. coli EMBacY competent cells, which contain
a baculovirus shuttle vector — a bacmid to generate the recombinant bacmids carrying
the genes of interest (79). Transformed cells were incubated at 37°C for 4hrs to allow the
pFastBac expression cassette to be incorporated into bacmids by the Tn7 transposon. The
culture was plated onto LB-Agar afterwards that contained 100µg/ml ampicillin, 50μg/ml
kanamycin, 10μg/ml tetracycline, 7μg/ml gentamycin, with 100μg/ml Xgal and 40μg/ml
IPTG to enable lacZ blue-white selection of the clones containing the gene of interest
(white colonies). The plates were incubated at 37°C for 1.5-2 days and then the white
colonies were re-streaked and re-evaluated by colony PCR. Positive clones were
amplified in an over-night LB medium containing 100µg/ml ampicillin, 50μg/ml
kanamycin, 7μg/ml gentamycin and 10μg/ml tetracycline at 37°C.
The recombinant pFastbac plasmids were purified via the Qiagen miniprep
protocol, while a modified version of this protocol was used to purify the recombinant
bacmid DNA. Cell pellets were resuspended in 300μl of Qiagen buffer P1, lysed by
addition of 300μl of Qiagen buffer P2 at room temperature for five minutes and then
incubated with 300μl of Qiagen buffer P3 on ice for ten minutes. The lysate was cleared
at room temperature by centrifugation at 13,000rpm for 10 minutes. The cleared lysate
700μl was added to 800μl ice cold isopropanol and incubated for 5 minutes on dry ice.
Precipitated bacmid DNA was pelleted by centrifugation at 13,000rpm for 10 minutes at
room temperature and the DNA pellet was washed with 70% (v/v) Ethanol. Eventually
the DNA was resuspended in 50μl of sterile elution buffer (Qiagen) inside a laminar flow
hood (sterile conditions).
The baculovirus of the genes of interest were generated for protein production,
and the Sf9 insect cell strain was used to amplify the baculovirus. Transfection mix was
made by adding 10µl of FuGene HD transfection reagent into 100µl of serum-free media
that contained 1-2µg of Bacmid DNA. The transfection mix was incubated at 27°C for 30
minutes before being diluted with 1ml serum-free medium and incubated with 2×106
healthy Sf9 cells in a 6-well plate. After transfection, another 2ml of serum-free medium
was added back into the Sf9 cells for continuous incubation at 27°C for 4-5 days before
the baculovirus was harvested. The 1st generation of virus needs to be amplified twice
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before being used for infection. The amplification was performed in 25mm cell culture
dishes with ~20×106 healthy Sf9 cells per dish. Each amplification mixture was made by
mixing 500µl of 1st generation virus with 5ml of serum-free medium. Then the
amplification mix was added into 25mm cell culture dishes before incubation at 27°C for
2 hours. After 2 hours, another 15ml of serum-free medium was added into each dish for
a continuous 3-day incubation at 27°C before the 2nd generation of baculovirus was
harvested. The 3rd generation of baculovirus was prepared with the same procedure.
Hi-5 insect cells were infected or co-infected by the 3rd generation of baculovirus
at a density of 10-20×106 cells/ml, and the infection was shaken at a speed of 120
revolutions per min (rpm) and incubated at 27°C for 2 hours in a shaker incubator. After
incubation, serum-free medium was added back to the infection and the cells were diluted
to a density of 1-2×106 cells/ml. The diluted infections were shaken at a speed of
155rpm/min and incubated at 27°C for one day and then at 20°C for anther two days
before harvesting. 1ml of virus was used for each 100ml infection culture and the viruses
used for co-infection were at a 1:1 ratio.
Protein expression and purification
Most of the protein complexes in this chapter were purified through GST and
Strep affinity tags. For these purification, Hi-5 insect cell pellets were resuspended in a
suspension buffer of 50mM Tris-HCl pH7.6, 0.3M NaCl, 5mM Dithiothreitol (DTT)
supplemented with 10µg/ml Aprotinin, 5µg/ml Leupeptin, protease inhibitor 1
tablet/50ml buffer (Sigma) and 2.5 mM phenylmethylsulphonyl fluoride (PMSF), and
lysed by sonication on ice. Lysates were cleared at 15,000rpm for 20 minutes at 4°C
twice, and the cleared lysates were incubated with glutathione-affinity resins (Qiagen) or
strep-tactin sepharose (IBA). Lysates were gently shaken on a rotary shaker at 4°C for 1
hour and then the beads were washed twice with two bead-volumes before loading onto
the column. Beads were washed in the column with at least 20 bead volumes before
elution. Proteins were eluted out of affinity beads by 10mM GSH (Glutathione) or
2.5mM dethiobiotin supplemented wash buffer (elution buffer), and the results were
visualized through SDS-PAGE. For the protein complexes that required removal of the
affinity tag, home made TEV protease, thrombin, or prescission was added to the elutions
at a mass ratio of 1:50, 1:100, 1:100 (protease: eluted proteins), respectively. The eluted
protein was concentrated to above 3mg/ml (measured by Bio-Rad Protein Assay) for the
tag cleavage.
For the native gel shift assay, protein complexes were purified by gel filtration
chromatography using a Superose6 column (GE) in a buffer of 50mM Tris-HCl pH7.6,
0.3M NaCl, 5mM DTT. The fractions of gel filtration were examined by SDS-PAGE to
select the protein fractions of interest. The fractions of interest were pooled, concentrated
with Amicon concenfugal filter units, aliquotted, flash-frozen in liquid nitrogen, and
stored at -80°C until later use.
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Native gel shift assays
The electrophoresis for the native gel shift assays was performed with 1×TB
buffer (90mM Tris-borate) pH 8.2. Native gels are a 4.5% poly-acrylamide gel with 2%
glycerol, made of 40% acrylamide/bis solution (37.5:1, Biorad), 100% glycerol and
5×TB buffer. Cdh1(full length or truncated)-Hsl130 was mixed with APC3ΔL-APC16 or APC8APC6-Cdc26-APC13 at a molar ratio of 10:1. APC3ΔL-APC16 or APC8-APC6-Cdc26APC13 were loaded with 21µM or 18µM for each mix, respectively. The mixes were
diluted with the gel filtration buffer, 50mM Tris-Cl pH7.6, 0.3M NaCl, 5mM DTT, to a
final volume of 8µl with 6.25% glycerol. For the control group, the same concentration of
the protein complexes were used as those in the experimental group and were directly
diluted by gel filtration buffer to 8µl with 6.25% glycerol. The diluted samples and mix
were incubated on ice for 20 minutes before electrophoresis was performed in the cold
room for 160mins (under 130V). The protein bands were visualized by commassie
staining.
WaterLOGSY
The purified protein complexes for WaterLOGSY screening were buffer
exchanged into 100mM phosphate-buffered saline (PBS) solution pH7.4 by NAP-5
columns (GE). Protein complexes were then mixed with TAME and diluted with 100mM
Na3PO4 pH7.0 buffer to a final volume of 500µl of 2mM protein complexes, 0.2mM
TAME and 10% D2O. The samples were transferred to NMR tubes at room temperature
and screened with a WaterLOGSY pulse sequence in Jet 600MHz (Bruker). All the
preparation before the sample transfer was done on ice or in the cold room. For each
sample, a reference spectrum and a 1D WaterLOGSY spectrum were recorded. Each
spectrum was scanned for 30 rounds, and each round includes 8 dummy scan and 32
scans.
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CHAPTER 4. IMPLICATIONS AND FUTURE DIRECTIONS
Insights from the Hybrid Structure of the C-terminal Portion of Human APC3
The structural study of the human C-terminal APC3 leads to its structure
determination. In the hybrid construct (the chimeric APC3), the C-terminal human APC3
folded into α-helices with the predicted TPR boundaries, whereas two TPR regions
folded into two α-helices instead of the canonical the α-helix-turn-α-helix (a TPR motif).
However, the binding groove of APC3 (TPR8-10) independently adopted a canonical
TPR folding without being affected by its neighbor mis-folded TPR7 and TPR11. The
details demonstrated by the atomic model of the APC3 binding groove provided an
accurate view to interpret current assays and help guide the design for later mutagenesis
study to validate the structure.
Although a mis-folded structure was generally considered to be uninformative,
the atomic model of the chimeric APC3 turned out to be useful for structure analysis. The
key information lies with a mis-folded helix α-11. The short alpha helix α-11 is folded
from the predicted TPR11. Instead of packing parallel to TPR10, it was recruited to the
binding groove. This phenomenon indicated the APC3 binding groove is functional even
it is surrounded with five mis-folded or mis-orientated α-helices. The residues mediating
the interactions between α-11 and the binding groove are different from those stabilizing
the canonical TPR11 packing (Figure 2-15). Although it couldn’t be concluded that the
formation of α-11 resulted from its recruitment to the binding groove, the fact of this misfolded helix indicates the binding groove is capable to mediate strong interactions and
affect the canonical folding pattern.
As to the binding groove TPRs 8-10, three dimensional structure alignments
showed that the whole binding groove well matched other canonical TPR motifs and the
α-11 overlapped with multiple binding partners of the matched hits (Figure 2-9).
Furthermore, the fact that the α-11 was aligned onto the binding partners implied that α11 potentially played a role of a pseudo binding partner in the chimeric APC3 (Figure
2-9).
Based on the fact that α-11 locked the chimeric APC3 binding groove as a
potential pseudo binding partner, the interactions between them partially represented the
recruitment mechanism of the APC co-activators. Similarly, two residues: a Lysine and a
Leucine, mimicked and represented the IR-tail (Isoleucine-Arginine) interactions,
although the Lys and Leu were along a turn of α-11 instead of a peptide. The carboxyl
group of the Lysine also formed a peptide bond. But these two residues (the Lysine an
Leucine) were recruited to two featured binding pockets respectively and demonstrated
the same types of the interactions as the IR-tails (Figure 2-10). The IR-tails have a free
carboxyl group, which most likely contributed to the recruitment by interacting with a
basic residue surrounding the negatively charged pocket. A highly conserved His551 of
TPR7a (Figure 2-16a), a well conserved His589 and Arg587 of TPR8a (Figure 2-8a,
Figure 2-10) are all close to the carboxyl group of IR-tail and could potentially mediate
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another salt bridge. The IR-tail probably established stronger interactions with the
binding groove than what were demonstrated by α-11 in the chimeric APC3.
The chimeric APC3 structure provided clues to speculate the biological meaning
of their interactions and a hypothetical model. Both the IR-tail residues and the APC3
binding groove residues are conservative across species. This may indicate that it is
critical to anchor the IR-tails (of the APC co-receptors) to the correct domain/region on
APC3. The IR-tail interactions would potentially be much stronger comparing to the
interactions of Cdh1 with APC8 and the APC platform (Figure 3-5, Figure 3-6, Figure
3-7).
The strong IR-tail interactions potentially keep the co-activators (Cdh1 and
Cdc20) and APC10 bound to the APC during APC active stages. Considering that Cdh1
repositioned itself on the APC during substrate recruitment and ubiquitination (31, 32),
the strong IR-tail interactions with APC3 would keep Cdh1 associating with the APC
during its orientation change. As for APC10, a constituent subunit of the APC, it has a
role for optimal Cdh1/Cdc20-dependent substrate recognition and substrate ubiquitination
processivity (38). However, it is not well understood how APC10 contributes to the
formation of poly-ubiquitin chains and whether it also has a movement on the APC. But
the IR-tail is the only domain of APC10 that connects to APC3, which potentially
requires the interactions strong enough to support the APC10 function.
The mis-folded TPRs inside the chimeric APC3 also provided clues for
speculation of TPR protein folding mechanism to understand the biological meaning of
their superhelix tertiary structure. The superhelix ensures the binding groove more
accessible to unstructured the peptides (etc. IR tails) rather than numerous, random αhelices surrounding APC3 (Figure 2-17). The correctly folded TPRs also served as an
accurate model for APCEM docking.
Strength and Weakness of Hybrid TPR Proteins/Technology
Brief introduction to the hybrid proteins strategy
The first successful hybrid protein was reported on the human Toll-like receptor
4. Toll-like receptors are a class of proteins that play a key role in the innate immune
system, and they belong to the Leucine rich repeats (LRR) protein family. LRR is a
protein structural motif composed of repeating 20–30 amino acids that are unusually rich
in the hydrophobic amino acid Leucine. Commonly a LRR motif forms an α helix-turn-β
strand, and these repeats pack parallel to each other and form a horseshoe-like solenoid.
The basic concept of hybrid proteins is to replace a crystallization hindrance
region of one protein with a homologous but crystallizable domain from its homologs
(Figure 2-1). The homologous domains were supposed to benefit crystallization without
changing or affecting the protein folding. The structure of human Toll-like receptor 4 was
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determined through a series of hybrids (65), because the receptor itself (full-length or
truncated) could not generate crystals. In order to help crystallization, the modules of
hagfish variable lymphocyte receptors (VLR) were fused to substitute the insoluble part
of the human toll-like receptor 4. These hybrid receptors crystallized and led to the
structure determination.
In pursuit of human APC3 structure, both the full-length or truncated APC3 could
not crystalize. The N-terminal E. cuniculi APC3 atomic structure was published around
that time, which includes the N-terminal TPRs 1-6 (PDB code: 3KAE). TPRs 1-4
mediate the E. cuniculi APC3 dimerization, followed by a 20-residue insert and TPR5-6
(Figure 2-1). However, the N-terminal dimerization domain of human APC3 expressed
poorly in vitro and the following disordered insert has 270 residues (Figure 2-1). These
two regions were both crystallization hindrance. Since the corresponding region in E.
cuniculi APC3 was crystallizable, it was used to substitute the insoluble domains of
human APC3.
Comparisons of LRR and TPR proteins
To this day, the hybrid technology has a couple successes in crystallizing LRR
(Leucine rich repeats) proteins. Another example is a hybrid InlB variant YopM-InlB.
InternalinB is an agonist of L. monocytogenes to the human receptor tyrosine kinase MET
(91). Whereas YopM is a surface effector of Y.pestis that binds caspase-1 to inhibit its
activity and sequesters it to block formation of a mature inflammasome (92). YopM and
InlB are two functionally non-related LRR proteins. The cap domain of YopM replaced
the cap of InlB protein, which originally folded into two α-helices but became shorter in
the hybrid protein. The residues at the hybrid interface also mildly shifted from original
positions, but the interface didn’t cause substantially global changes of the InlB structure
(66). The hyrbrid YopM-InlB addressed the biological function of the N-terminal cap of
internalins, which could not be studied with simple domain deletion constructs due to its
indispensability to correct protein folding.
Although both LRR and TPR proteins are featured with repeat structure motifs,
they are quite different. The difference of LRR proteins and TPR proteins are listed in the
Table 4-1. Repeat proteins are involved in many important protein–protein interactions in
most organisms, and LRR proteins have more rigid structural motifs to make their tertiary
structures more repeatable among each other. Most LRR proteins form solenoid
structures of a horseshoe with the motifs of an α-helix/β-strand. Structures of four
functionally non-related LRR proteins are well superimposed onto each other and the
overlapped horseshoes have elongated and curved shapes with similar radii, although the
length of each protein vary (Figure 4-1, left).
The conserved structural packing of the LRR family is probably contributed from
their consensus sequence of the structural motifs, which is enriched with Leucine and a
few other hydrophobic residues. For example, the consensus sequence in the LRR motif
of human TLR4 (Toll-like receptor 4) consists of Leucine and Phenylalanine. These two
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Table 4-1.
Comparison of LRR (Leucine rich repeat) and TPR
(Tetratricopeptide repeat) proteins.
Comparisons
Motifs
Packing
Folding

Consensus
sequence

Repeat unit
Function

LRR proteins
(Leucine rich repeats)
An α-helix-turn-β-strand
Stacking to form solenoid
structures of a horseshoe
Independently folding, long
or short hybrids folds
correctly)

TPR proteins
(Tetratricopeptide repeats)
Two antiparallel helices
Paralleling to solenoid
structures of a super helix
Less conserved TPRs, tend to
depend on the neighbor TPRs
or the protein tertiary
structures
More conserved consensus
Consensus sequence of
sequence of structural motifs structural motifs are not
(from a large number of
identified
functionally unrelated
proteins)
310-helices in a strict length
Repeat units of an average 34
(of one motif)
residues (one TPR motif)
Protein scaffold, mediate
Protein scaffold, mediate
protein-protein interactions
protein-protein interactions
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Figure 4-1. Leucine rich repeat proteins have repeatable structural framework
with rigid structural motifs.
Left: A structural superimposition of five different LRR proteins, with the name and PDB
code of each protein labeled in the same color as the backbone in the structures.
Right: Illustration of the interactions that stabilize the packing of structure motifs in the
human toll-like receptor 4. The warm pink sticks indicate Leucine and purple sticks
indicate Phenylalanine.
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residues mainly mediate the inter-motif and intra-motif packing (Figure 4-1, right) and
the simple interaction pattern is potentially responsible for rigid repeat units, which
results in human TLR4 has a repeatable scaffold (tertiary structure) as other LRR proteins
Comparing to the LRR proteins interaction pattern, TPR proteins demonstrate
complicate interaction “networks”. TPR protein is featured by TPR motifs packed
parallel to each other. Instead of stacking to form an elongated horseshoe, most TPR
proteins fold into a superhelix with their TPRs. The “networks” are possible because one
α-helix of a TPR motif is usually surrounded by four other α-helices, rather than being
simply flanked by an upstream and a downstream α-helices. This local architecture
allows one helix close to four α-helices and the center α-helix could establish interactions
with all four of them. Both human APC3 and APC6 demonstrate this structure (Figure
4-2).
Sharing the complexity inside the TPR interaction networks, TPR protein residues
that mediate the interactions show high diversity comparing to the LRR proteins. The
rigid LRR motifs have consensus sequence, which make the LRR protein folding more
predictable. Contrastingly, no consensus sequence could be identified for TPR motifs.
Instead, TPR motifs use various hydrophobic residues to organize/support/build up the
interaction networks. For instance, human APC3 TPR9a contacts TPR 8a and 10a besides
establishing packing interactions with two neighbor α-helices TPR 8b and 9b (Figure
4-2, left). A Tyr and a Leu of human APC3 TPR9a interact with a Glu and an Asn of the
TPR8a, respectively, and an Ala from TPR9a interacts with a His of TPR10a. In another
example of human APC6, APC6 TPR8b contacts an Ile and a His of TPR7b with a Pro
and a Tyr, whereas two Leu on the other side of the TPR8b contact with two Val of
TPR9b (Figure 4-2, right). The residues to mediate intra-TPR interactions could include
all hydrophobic residues instead of a few. Furthermore, all these residues show no
repeatable or predictable positions in the protein sequence. There are more complexities
in TPR protein folding with respect to interaction networks and protein sequence.
The strength and weakness of the TPR hybrid technology
There are advantages of hybrid protein technology. Generally, the successful
hybrid proteins have better behaviors and showed the higher potential for crystallization,
which offer the opportunities for structure studies and determination. Through the
chimeric APC3 structures, it seems like the highly conserved TPR domains have higher
chance to follow canonical folding in the hybrid proteins. The structures of these
conserved domains provide the guidance for further studies and experimental designs. On
the other hand, it is interesting to know that TPR proteins have the potential to adopt
alternative folding to be soluble. Biologically, this could lower down the cell stress when
the gene mutations happen or protein-folding machineries make mistakes. Furthermore,
the domain swapping strategy also creates an approach to test the function of an essential
domain which could neither be separated from the original protein nor be functional on
its own (66).
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Figure 4-2.
packing.

TPR proteins have interaction networks involved in TPR motif

Illustration of TPR protein interaction networks from human APC3 (left) and APC6
(right), with the residues mediating the interactions labeled out with lines and sticks. The
lines indicate that residues mediate the center α-helix packing to its neighbor α-helices,
and those residues are shown in the bottom sequence in black color. Similarly, sticks
indicate the residues involved in the center α-helix contacting distant α-helices and they
are shown at the bottom in green (human APC3, left) and orange (human APC6, right).
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However, the risks of TPR hybrids are higher than the LRR hybrids. The interface
of a hybrid protein potentially affects the downstream protein peptide folding since both
LRR and TPR proteins pack based on the interaction among their consecutive structural
units. Because TPR proteins are featured with more complicate interactions (cross-TPRs)
mediated by a variety of residues, they are more sensitive to the domain swap. The hybrid
YopM-InlB has the motif immediately following the YopM cap affected, while the rest of
the hybrid protein kept the same scaffold (66). In the chimeric APC3, TPR7 failed to be
stabilized by TPR6 and leads to the orientation of the whole protein changed.
Combining the consensus sequence and available atomic structures, the
hydrophobic cores of LRR proteins are more stable and predictable than TPR proteins.
Synthetic libraries of designed LRR proteins have been designed and used for generating
artificial binders that replace antibodies (93). So far there is no such libraries for TPR
proteins. However, the available atomic models from TPR proteins are increasing, which
help to improvement from the protein structure prediction and analysis. As for TPR
protein hybrids, the combination of multiple approaches will be required to design
successful fusion structures, i.e. the homologous atomic models, structure prediction,
EM-derived models. Meanwhile, the following strict and careful analyses are also
essential to examine the authenticities of atomic structures.
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APPENDIX. SUPPLEMENTARY DATA FOR STRUCTURAL STUDIES OF THE
TPR SUBUNITS OF THE HUMAN APC

Figure A-1.
APC3.

Intact masspectra of the SeMet incorporated and native chimeric

The molecular weight of the SeMet incorporated and native chimeric APC3 are
42198.93Da and 41684.77 Da, detected by the Intact masspectrometry. A
SelenoMethione has a molecular weight of 196.11Da and a Methionine weight 149.21Da.
The incorporated Selenium sites are about 10 for each purified protein, which is
calculated from (42198.93-41684.77)/(196.11-149.21)=10.35.
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Figure A-2.

Different crystal forms of the chimeric APC3.

Different crystal forms of the SeMet labeled (top), MBP-(AAA)- fused (middle), and
Lysine methylated chimeric APC3, with the schematics of the corresponding constructs
on the left. The crystallization conditions are:
Top: 0.1M HEPEs pH 7.0, 0.2M AmSO4, and 48-51% MPD, at room temperature.
Middle: 0.1M BTP pH7.5, 20% PEG3350, and 0.2M NaI, at room temperature.
Bottom: Lysine methylated 0.1M CAPS pH10.5 and 40% MPD, at 4°C.
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Figure A-3.

The structural comparison of the N-terminal APC7 and APC3.

The 3D superimposition of the N-terminal human APC7 TPR1-4 (PDB code: 3FFL) onto
the EM-derived human APC3 (TPR1-4). The α-helices are displayed in the shapes of
cyclinders with the TPR numbers labeled.
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Table A-1.
Complex

A crystallization summary of the APC TPR subunits.
Details

APC3ΔL- Human APC3Δ(183-452),
APC1674 with APC16 residues 74110, co-purified,
stoichiometry 2:1
APC3ΔL- Human APC3Δ(183-452),
APC1674- APC16 residues 74-110,
Cdh1flCdh1 full-length and yeast
Hsl130
Hsl1 includes KEN and D
box, co-purified,
stoichiometry 2:1:2:2
APC8flHuman APC8 full-length
APC6swith APC6residues 212-539,
Cdc26s
Cdc26 residues 1-29, copurified, stoichiometry 1:1:1
APC8flAPC6lCdc26s
APC8flAPC6flCdc26fl

Human APC8 full-length
with APC6residues 1-539,
Cdc26 residues 1-29, copurified, stoichiometry 1:1:1
Human and zebrafish fulllength proteins of APC8,
APC6, Cdc26, co-purified,
stoichiometry 1:1:1

Crystalization
screening description
Robotic screen around
2,000 conditions at 4°C
& RT

Hits
Yes

Crystal optimization
summary
Robotic screening of 250
conditions and manual
screening/optimization in 500
conditions
Robotic screening of 96
additives and manual
screening/optimization in 290
conditions

Results
Diffraction
around 5Å

Robotic screen around
2,000 conditions at 4°C
& RT

Yes

Robotic screen around
2,600 conditions at 4°C
& RT for each complex
4°C & RT

Yes

Robotically and manually
screen 360 conditions

Robotic screen around
2,800 conditions at 4°C
& RT for each complex
4°C & RT
Robotic screen around
2,400 conditions at 4°C
& RT for each complex

No

—

Diffraction
around 3Å,
but APC8
doesn't pack
in the crystals
—

No

—

—
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Diffraction
around 7Å

Figure A-4.

Crystallization of the human APC3∆L-APC1674.

A brief summary of the purification and the crystallization of the human APC3∆LAPC1674. Each component of the protein complex is schematically illustrated (top panel)
The middle panel is a gel filtration profile from the purification of the protein complex
(left), with the complex fractions examined by SDS-PAGE (right). The pooled fractions
are labeled out with a purple line at the bottom of the gel. The purified APC3∆LAPC1674 generated hits in the condition of 0.1M BTP pH 7.5, 10% PEG3350 at room
temperature (bottom left) and the crystals diffracted to ~6Å.
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Figure A-5.

The crystallization summary of APC3∆L-APC1674-Cdh1-Hsl30.

A brief summary of the purification and the crystallization of the human APC3∆LAPC1674-Cdh1-Hsl30. Each component in the protein complex is schematically illustrated
(top panel). The middle panel is a gel filtration profile from the purification of the protein
complex (left), with the complex fractions examined by SDS-PAGE (right). The pooled
fractions are labeled out with a purple line at the bottom of the gel. The purified
APC3∆L-APC1674-Cdh1-Hsl30 generated hits at 4˚C in the conditions of 0.1M BTP pH
7.0, 0.4M Mg-Formate (bottom left) and 0.1M MES pH 6.5, 0.5M AmSO4 (bottom
middle). The crystals diffracted to ~7Å.
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Figure A-6. Human Cdh1 N-terminal secondary structure prediction from
Psipred (68).
The human Cdh1 sequence refers to 496 a.a (Uniprot code: Q9UM11). The pink
cylinders indicate the α-helices and yellow arrows indicate the β-sheets. The residue
numbers are labeled under the protein sequence.
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